Engineered alpha-GAL A peptides and functional variants thereof and related methods for treating Fabry disease

The prior art α-GAL A expression and Gb3 were solved by using engineered peptides containing α-GAL A and heterologous signal peptides and rAAV vectors in the treatment of Fabri disease to deliver α-GAL A to targeted tissues. The problem of poor cleaning results has been eliminated, achieving a more lasting and safer therapeutic effect.

CN117551636BActive Publication Date: 2024-11-08SICHUAN REAL&BEST BIOTECH CO LTD
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202310956377.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2023-07-25
Filing Date
2023-07-31
Publication Date
2024-11-08
Estimated Expiration
2043-07-31

AI Technical Summary

Technical Problem

Existing Fabry disease treatments such as enzyme replacement therapy and recombinant adeno-associated viral drugs have limited effects on the expression of α-GAL A and Gb3 clearance, and there are problems with safety and long-lasting effects.

Method used

Using engineered peptides containing α-GAL A or its functional variant and heterologous signal peptide, combined with viral vectors, using recombinant adeno-associated viral vectors by delivering α-GAL A to targeted tissues to increase their expression, secretion and activity. (rAAV) for gene therapy.

Benefits of technology

The expression and activity of α-GAL A in targeted tissues was significantly improved, the scavenging ability of Gb3 and lyso-Gb3 was enhanced, and more durable and safe therapeutic effects were provided.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117551636B_ABST
    Figure CN117551636B_ABST
Patent Text Reader

Abstract

An object of the present technology is to provide novel compositions for increasing the expression of α-GAL A and related methods of using such novel compositions to treat Fabry disease and / or symptoms of Fabry disease.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related Applications

[0002] This application claims priority to U.S. Provisional Application Nos. 63 / 499,243 and 63 / 515,558, filed on April 30, 2023 and July 25, 2023, entitled “ENGINEERED ALPHA-GALACTOSIDASE A (Α-GAL A) PEPTIDES AND FUNCTIONAL VARIANTS THEREOF ANDASSOCIATED METHODS OF TREATING FABRY DISEASE,” the entire contents of which are incorporated herein by reference in their entirety. Background Art

[0003] Fabry disease is an X-linked lysosomal storage disease characterized by α-galactosidase A (α-GALA) deficiency, which may lead to the progressive and systemic accumulation of sphingolipids, such as globotriaosylceramide (Gb3) and globotriaosylsphingosine (lyso-Gb3), in the lysosomes of vascular endothelial cells, renal epithelial cells and endothelial cells, cardiomyocytes, etc. Sphingolipid deposition may lead to skin, heart, kidney, cerebrovascular and other diseases, and ultimately lead to premature death of patients.

[0004] Treatment options for Fabry disease are limited, including enzyme replacement therapy (ERT), which delivers recombinant human α-GAL A intravenously (J Med Gene 2015 May;52(5):353-8). Although ERT can be effective, especially in the early stages of the disease, α-GAL A has a relatively short half-life and patients often require regular infusions (N Engl J Med. 2001 Jul 5;345(1):9-16), resulting in a lifelong burden. Recently, oral drug partners have been developed to treat Fabry disease. It is approved for the treatment of Fabry disease, but it is only effective against certain α-GAL A mutations. In addition, there are three recombinant adeno-associated virus (rAAV) drugs in clinical trials, each of which uses a different rAAV serotype, specific promoter, and other mechanisms to promote the expression of α-GAL A (NCT04046224 / NCT05039886, NCT04519749, and NCT04040049). However, rAAV-mediated expression of α-GAL A and clearance of the disease substrates Gb3 and lyso-Gb3 remain limited.

[0005] Despite these available therapies, there remains a need for new treatments for Fabry disease that are safe, effective, and have durable effects. Summary of the invention

[0006] One object of the present technology is to provide novel compositions for increasing the expression of α-GAL A and related methods of using such novel compositions to treat Fabry disease and / or symptoms of Fabry disease.

[0007] Unless otherwise specified, α-GAL A refers to the amino acid sequence of mature α-GAL produced after the wild-type signal peptide (wt sp) is cleaved, or a functional variant thereof; precursor or full-length α-GAL A refers to α-GAL fused to one or more signal peptides, and the signal peptide may be wt sp or a heterologous sp, such as but not limited to sp1, sp2, ... and sp22 disclosed in Table 2; hGLA refers to a nucleotide sequence encoding α-GAL A, such as wild-type human α-galactosidase a (wt hGLA) and an optimized / modified nucleotide sequence encoding α-GLA a or a functional variant thereof (such as hGLA cov1 disclosed herein); lowercase sp refers to a signal peptide or a functional variant thereof, and uppercase SP refers to a nucleotide sequence encoding a signal peptide or a functional variant thereof. The signal peptide referred to by sp may be wt sp or a heterologous sp, and the nucleotide sequence SP encoding the signal peptide may be a nucleotide sequence encoding wt sp or a heterologous sp.

[0008] In some embodiments, the composition comprises an engineered peptide comprising α-GAL A or a functional variant thereof, a signal peptide of tissue plasminogen activator (sp21) or a functional variant thereof, and an optional cell-penetrating peptide or a functional variant thereof. In some embodiments, the composition comprises a viral vector comprising an expression cassette comprising a first nucleotide sequence encoding α-GAL A or a functional variant thereof, a second nucleotide sequence encoding sp21 or a functional variant thereof, an optional third nucleotide sequence encoding a cell-penetrating peptide or a functional variant thereof, and a promoter.

[0009] In some embodiments, the composition comprises an engineered peptide comprising α-GAL A or a functional variant thereof, a wild-type signal peptide (wt sp) of α-GAL or a functional variant thereof, and an optional cell-penetrating peptide or a functional variant thereof. In some embodiments, the composition comprises a viral vector comprising an expression cassette comprising a first nucleotide sequence encoding α-GAL A or a functional variant thereof, a fourth nucleotide sequence encoding wt-sp or a functional variant thereof, and an optional third nucleotide sequence encoding a cell-penetrating peptide or a functional variant thereof and a promoter.

[0010] Another object of the present technology is to provide a method for treating Fabry disease in a subject or alleviating one or more symptoms of Fabry disease in a subject by administering the composition to the subject.

[0011] One object of the present technology is to provide a method for increasing the expression of α-GAL A in one or more targeted tissues of a subject by administering the composition to the subject.

[0012] One object of the present technology is to provide methods for reducing sphingolipid storage in one or more targeted tissues of a subject by administering the composition to the subject.

[0013] These and other objects are apparent from the following detailed description and accompanying drawings. The present technology includes engineered peptides comprising or consisting of a portion of α-GAL A or a functional variant thereof and at least a portion of a heterologous signal peptide, and viral vectors encoding the engineered peptides. The present technology produces beneficial disease treatments by increasing α-GAL A expression, secretion, distribution, and activity to treat or alleviate Fabry disease.

[0014] In some embodiments, the engineered peptide comprises α-GAL A or a functional variant thereof and a heterologous signal peptide (e.g., sp21) or a functional mutant thereof. Other examples of heterologous signal peptides include, but are not limited to, sp1-sp20 and sp22. In certain embodiments, the heterologous signal peptide is selected from the group consisting of sp1, sp3, sp4, sp18, sp20, and sp22 disclosed herein. α-GAL A or its functional variant may or may not contain the wild-type (wt) signal peptide of α-GAL.

[0015] In some aspects, engineered peptides also include cell-penetrating peptides or their functional variants. Examples of cell-penetrating peptides include but are not limited to TAT p47-57, TAT p48-60, penetrant (Penetratin) p43-58, hCT (human calcitonin, human calcitonin) p9-32, polyarginine (R7-R25), pVEC, Pep-1, transporter (Transportan) and MAP.

[0016] In some aspects, α-GAL A or a functional variant thereof comprises a polypeptide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO:27.

[0017] In some aspects, sp1, sp3, sp4, sp18, sp20, sp21 and sp22 or their functional variants comprise a polypeptide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 29, 31, 32, 46, 48, 49 and 50, respectively.

[0018] In some aspects, the signal peptide or a functional variant thereof comprises a polypeptide peptide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to the polypeptide peptide sequence of SEQ ID NO: 29, 31, 32, 46, 48, 49 and 50.

[0019] In some aspects, the cell-penetrating peptide or a functional variant thereof comprises a polypeptide peptide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to a polypeptide peptide sequence selected from the group consisting of TAT p47-57 (SEQ ID NO: 55), TAT p48-60 (SEQ ID NO: 56), penetratin p43-58 (SEQ ID NO: 57), CF-hCT p9-32 (SEQ ID NO: 58), polyarginine (SEQ ID NO: 59), pVEC (SEQ ID NO: 60), Pep-1 (SEQ ID NO: 61), transportin (SEQ ID NO: 62) and MAP (SEQ ID NO: 63).

[0020] In some aspects, a heterologous signal peptide (e.g., sp21) or a functional variant thereof is fused to the N-terminus of a portion of α-GAL A or a functional variant thereof. In certain aspects, a portion of a heterologous signal peptide (e.g., sp21) or a functional variant thereof is fused to the C-terminus of α-GAL A or a functional variant thereof. In some aspects, a portion of a heterologous signal peptide (e.g., sp21) or a functional variant thereof is fused to the interior of α-GAL A or a functional variant thereof.

[0021] In some aspects, the cell-penetrating peptide or its functional variant is fused to the C-terminus of α-GAL A or its functional variant. In certain aspects, the cell-penetrating peptide or its functional variant is fused to the N-terminus of α-GAL A or its functional variant. In some aspects, the cell-penetrating peptide or its functional variant is fused to the interior of α-GAL A or its functional variant.

[0022] In some embodiments, the present technology further comprises a viral vector having a nucleotide sequence encoding the engineered peptide.

[0023] In some aspects, the viral vector further comprises a promoter.

[0024] In some embodiments, the composition of the present technology comprises a viral vector comprising an expression cassette, the expression cassette comprising or consisting of a first nucleotide sequence encoding α-GAL A or a functional variant thereof and a second nucleotide sequence encoding a heterologous signal peptide (e.g., sp21) or a functional variant thereof. In some embodiments, the composition of the present technology comprises a viral vector having an expression cassette, the expression cassette comprising or consisting of a first nucleotide sequence encoding α-GAL A or a functional variant thereof, a fourth nucleotide sequence encoding a wt-sp portion or a functional variant thereof, and optionally a third nucleotide sequence encoding a cell-penetrating peptide or a functional variant thereof and a promoter.

[0025] In some aspects, the second or fourth nucleotide sequence is located 5' to the first nucleotide sequence, and / or the third nucleotide sequence is located 3' to the first nucleotide sequence.

[0026] Another aspect described herein is a viral vector, wherein the nucleotide sequence encoding a portion of α-GAL A or a functional variant thereof is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 25 or 26.

[0027] In some aspects, the nucleotide sequence encoding sp21 or a functional variant thereof is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO:22.

[0028] In some aspects, the nucleotide sequence encoding the wt-sp portion or its functional variant portion is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 1 or 51.

[0029] In some aspects, the nucleotide sequence encoding the heterologous signal peptide or a functional variant thereof has at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NOs: 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22 and 23.

[0030] In some aspects, the nucleotide sequence encoding the heterologous signal peptide or a functional variant thereof is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to the nucleotide sequence of SEQ ID NOs: 2, 4, 5, 19, 21, 22 and 23.

[0031] In some aspects, the nucleotide sequence encoding the cell-penetrating peptide or a functional variant thereof is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO:24.

[0032] In some aspects, the nucleotide sequence encoding the cell-penetrating peptide or a functional variant thereof is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to the nucleotide sequence of SEQ ID NO: 24, 52, 53 and 54.

[0033] In some aspects, the promoter is a tissue-specific promoter.

[0034] In some aspects, the tissue-specific promoter is a liver-specific promoter, a cardiac-specific promoter, or a kidney-specific promoter.

[0035] In some aspects, the liver-specific promoter is the TTR promoter.

[0036] In some aspects, the viral vector further comprises at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

[0037] In some aspects, the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

[0038] In some embodiments, the present technology also includes methods of treating Fabry disease in a subject or alleviating one or more symptoms of Fabry disease in a subject by administering a composition to the subject.

[0039] In some embodiments, the present technology also includes methods of increasing α-GAL A expression in one or more targeted tissues of a subject by administering the composition to the subject.

[0040] In some embodiments, the present technology also includes methods of reducing sphingolipid storage in one or more targeted tissues of a subject by administering a composition to the subject.

[0041] In some aspects, the subject has Fabry disease or has symptoms of Fabry disease.

[0042] In some aspects, the one or more targeted tissues are selected from liver tissue, heart tissue, or kidney tissue.

[0043] In some aspects, the method further comprises administering a composition of the present technology to the subject.

[0044] In some aspects, a composition of the present technology is administered to a subject once.

[0045] In some aspects, compositions of the present technology are administered to a subject by systemic administration.

[0046] In some aspects, compositions of the present technology are administered to a subject by topical administration.

[0047] In some aspects, compositions of the present technology are administered to a subject via specific organ administration.

[0048] In some aspects, the viral vectors of the compositions comprising the viral vectors of the present technology are administered to a subject at one or more doses of 1E+11 vg / kg to 5E+14 vg / kg. BRIEF DESCRIPTION OF THE DRAWINGS

[0049] Figure 1A and 1B Shown are embodiments of engineered recombinant adeno-associated virus (rAAV) vectors of the present technology. The rAAV vector comprises an expression construct having a human α-galactosidase a (hGLA) nucleotide sequence and a nucleotide sequence encoding a signal peptide (sp). The hGLA nucleotide sequence can be wild-type hGLA (hGLA wt) or an optimized nucleotide sequence encoding α-GAL A (hGLAc.o.v1). The signal peptide nucleotide sequence can be a wild-type nucleotide sequence encoding a wild-type sp of α-GAL A (wt SP), an optimized nucleotide sequence encoding a wild-type signal peptide of α-GAL A (wtSP co), or a nucleotide sequence encoding a heterologous sp, such as sp1 to sp22 disclosed herein (respectively referred to as SP1 to SP22). Figure 1A and 1B The structures of rAAV vectors comprising nucleotide sequences encoding wt sp (wt SP or wtSP co) or sp21 (SP21) are shown. Figure 1A Two examples of single-stranded rAAV vectors (ss-rAAVs) are shown: ss-wtspGLA comprising wt SP and hGLA wt; and ss-sp21GLA comprising SP21 and hGLA wt. Figure 1B Multiple examples of self-complementary vectors (sc-rAAVs) are shown: FD802-1 comprising wt SP and hGLA wt; FD802-2 comprising SP21 and hGLA wt; FD802-3 comprising wtSP co and hGLA cov1; FD802-4 comprising SP21 and hGLA cov1; FD802-5 comprising wtSP co, hGLA cov1 and a wild-type nucleotide sequence (tat) encoding TAT (e.g., TAT sequence p47-57, TAT sequence p48-60).

[0050] Figure 2A and 2B The results show that the expression level of α-GAL A in the cell culture medium of HepG2 cells transfected with plasmids expressing α-GAL A + heterologous sp (sp1, sp2, ... and sp22) was significantly higher than that of cells transfected with plasmids expressing α-GAL A + wt sp ( Figure 2A ) and activity level ( Figure 2B )Increase.

[0051] Figure 3A -B shows the viral vector genome levels of ss-rAA ​​in the liver of Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A + sp21 (ss-sp21GLA), Fabry mice expressing ss-rAAV expressing α-GAL A + wt sp (ss-wtspGLA), or untreated Fabry mice (0 vg / kg dose) ( Figure 3A ) and hGLA mRNA levels ( Figure 3B ).

[0052] Figure 4 It was shown that the activity level of α-GAL A in the plasma of Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg) or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA), or ss-rAAV expressing α-GAL A+wt sp (ss-wtspGLA) was increased compared with untreated Fabry mice (untreated) and untreated wild-type mice (wild-type).

[0053] Figure 5A -D shows that the liver of Fabry mice injected with low (2E+12vg / kg), medium (5E+12vg / kg), and high (5E+13vg / kg) doses of ss-rAAV expressing α-GAL A + sp21 (ss-sp21GLA) was significantly increased compared with that of Fabry mice injected with low (2E+12vg / kg), medium (5E+12vg / kg), and high (5E+13vg / kg) doses of ss-rAAV expressing α-GAL A + wt sp (ss-wtspGLA), untreated Fabry mice (untreated), and untreated wild-type mice (wild-type). Figure 5A ),kidney( Figure 5B ),Heart( Figure 5C ) and spleen ( Figure 5D ) increased the activity level of α-GAL A in

[0054] Fig. 6A-B shows the increase of α-GAL A expression in the liver of Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A + sp21 (ss-sp21GLA) compared with Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A + wt sp (ss-wtspGLA) ( Fig. 6A ), and an increase in glycosylated α-GAL A in the liver of Fabry mice injected with a high (5E+13 vg / kg) dose of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA) compared to Fabry mice injected with a high (5E+13 vg / kg) dose of ss-rAAV expressing α-GAL A+wt sp (ss-wtspGLA). Figure 6B ).

[0055] Figure 7 It was shown that 12 weeks after injection of a high dose (5E+13 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA), the expression of α-GAL A was increased in the liver, heart, and kidney of Fabry mice compared with Fabry mice injected with a high dose (5E+13 vg / kg) of ss-rAAV expressing α-GAL A+wt sp (ss-wtspGLA) or untreated Fabry mice.

[0056] Fig. 8A -B shows that plasma lyso-Gb3 levels were increased 12 weeks after injection in Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A + sp21 (ss-sp21GLA) compared with untreated Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A + sp21 (ss-sp21GLA). Fig. 8A ) and 26 weeks ( Figure 8B ) decreased on average.

[0057] Fig. 9Shown are changes in body weight of untreated Fabry mice (untreated), wild-type mice (wild-type), Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A+wt sp (ss-wtspGLA), and Fabry mice injected with low (2E+12 vg / kg), medium (5E+12 vg / kg), or high (5E+13 vg / kg) doses of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA).

[0058] Fig.10 The liver tissues of Fabry mice injected with high doses (5E+13 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA), Fabry mice injected with high doses (5E+13 vg / kg) of ss-rAAV expressing α-GAL A+wt-sp (ss wtspGLA), untreated Fabry mice, and wild-type mice without Fabry disease were shown. After high-dose administration of ss-wtspGLA and ss-sp21GLA, there were no obvious histopathological changes in the liver, indicating that the therapeutic administration has a certain safety.

[0059] Fig.11 The results show that the expression of α-GAL in HepG2 protein lysate increased after transfection with a plasmid expressing α-GAL A encoded by the nucleotide sequence of the functional variant hGLA (hGLA cov1, SEQ ID NO: 26), compared with cells transfected with a plasmid expressing wt hGLA nucleotide sequence and untransfected cells (negative control, NC). GAPDH was used as a loading control for Western blotting experiments.

[0060] Fig.12It was shown that the activity of α-GAL A in the plasma of Fabry mice (FD802-3 and FD802-4) injected with low (2E+12 vg / kg) or medium (5E+12 vg / kg) doses of sc-rAAV expressing α-GAL A encoded by the nucleotide sequence hGLA cov1 of the functional variant hGLA increased compared to Fabry mice (FD802-1 and FD802-2) injected with low (2E+12 vg / kg) or medium (5E+12 vg / kg) doses of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA), as well as untreated Fabry mice (untreated).

[0061] Fig.13 It was shown that after injection of a medium dose (5E+12 vg / kg) of FD802-1, FD802-2, FD802-3 and FD802-4, α-GAL A activity was increased in the liver, heart, kidney and spleen of Fabry mice compared with Fabry mice injected with a medium dose (5E+12 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA) and untreated Fabry mice (untreated).

[0062] Fig.14 It was shown that the activity of α-GAL A in the liver of Fabry mice was increased after injection of a medium dose (5E+12 vg / kg) of FD802-1, FD802-2, FD802-3 and FD802-4, compared with Fabry mice injected with a medium dose (5E+12 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA) and untreated Fabry mice (untreated).

[0063] Fig.15 It was shown that the protein of α-GAL A in the liver of Fabry mice increased after injection of a medium dose (5E+12 vg / kg) of FD802-1, FD802-2, FD802-3 and FD802-4, compared with Fabry mice injected with a medium dose (5E+12 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA) and untreated Fabry mice.

[0064] Fig.16The results showed that the levels of glycosylated α-GAL A in the liver of Fabry mice were increased after injection of a medium dose (5E+12 vg / kg) of FD802-3 and FD802-4 relative to Fabry mice injected with a medium dose (5E+12 vg / kg) of FD802-1 or FD802-2. Recombinant α-GAL A was used as a positive control (Rec. hAGA) for the in vitro glycosylation assay.

[0065] Fig.17A -B shows that the plasma levels of lyso-Gb3 in Fabry mice injected with a medium dose (5E+12 vg / kg) of FD802-1, FD802-2, FD802-3, and FD802-4 were significantly increased at 6 weeks post-injection (Figure 5A). Fig.17A ) and 14 weeks after injection ( Fig. 17B ) both decreased.

[0066] Fig.18 The results of histopathological staining of the livers of Fabry mice injected with a medium dose (5E+12 vg / kg) of FD802-1, FD802-2, FD802-3, and FD802-4 are shown, compared to Fabry mice injected with a medium dose (5E+12 vg / kg) of ss-rAAV expressing α-GAL A+sp21 (ss-sp21GLA) and untreated Fabry mice (untreated). There were no obvious histopathological changes in the liver after administration, indicating that the therapeutic administration was safe.

[0067] Fig.19A -B demonstrates the correlation between vector serotype (rAAV1, rAAV2, ..., rAAV10) and α-GAL A expression (lysate) and secretion (culture medium) in HepG2 cells ( Fig.19A The genomes of the sc-AAVs of different serotypes used for transduction were the same as those of FD802-4, and contained the functional variant hGLA nucleotide sequences (hGLA cov1, SEQ ID NO: 26) and SP21 (SEQ ID NO: 22). Fig.19B Activity analysis of secreted α-GAL A is shown. NC: negative control, protein sample from HepG2 cells not transduced with AAV. PC: positive control, protein sample containing α-GAL A.

[0068] Fig. 20A -B illustrates the effect of including the nucleotide sequence encoding TAT p47-57 in the plasmid expressing α-GAL A on the activity of α-GAL A in cell culture medium. Fig. 20A It was shown that, compared with the plasmid (GLAco) containing the functional variant hGLA nucleotide sequence (hGLA cov1, SEQ ID NO: 26), the functional variant wtsp nucleotide sequence located at the N-terminus (wtSP co, SEQ ID NO: 51), and the tat nucleotide sequence (SEQ ID: 24) located at the C-terminus, the α-GAL A activity level produced in the cell culture medium by transfection of the plasmid (Ctat-GLAco) containing the functional variant hGLA nucleotide sequence (hGLAc.o.v1, SEQ ID NO: 26) and the functional variant wtsp nucleotide sequence located at the N-terminus (wtSP co, SEQ ID NO: 51) was lower. Fig. 20B The results showed that the α-GAL A expressed by the two plasmids had comparable enzyme activities.

[0069] Fig.21A -B shows that the activity of α-GAL A in the plasma of Fabry mice increased after injection of low (2E+12 vg / kg) or medium (5E+12 vg / kg) doses of FD802-5 relative to untreated Fabry mice, but there was no change in activity compared to the equivalent dose of FD802-3 ( Fig.21A The activity levels of α-GAL A in the liver, heart, kidney, and spleen tissues of Fabry mice injected with a medium dose (5E+12 vg / kg) of FD802-3 or FD802-5 and untreated Fabry mice were also shown ( Fig. 21B ).

[0070] Fig. 22 It was shown that the protein of α-GAL A was increased in the liver, heart and kidney of Fabry mice after injection of a medium dose (5E+12 vg / kg) of FD802-5, relative to the examples of comparable doses of FD802-3 and the untreated example (untreated).

[0071] Fig.23A -B shows the expression of α-GAL A in the liver of Fabry mice 14 weeks after injection of a medium dose (5E+12 vg / kg) of FD802-3 and FD802-5 ( Fig.23A ) and glycosylation ( Fig. 23B ). Recombinant α-GAL A was used as a positive control for in vitro glycosylation assay (Rec.hAGA).

[0072] Fig.24A -B shows that Fabry mice injected with low (2E+12 vg / kg) or medium (5E+12 vg / kg) doses of FD802-3 and FD802-5 showed significant increases in Fabry mice at 6 weeks post-injection ( Fig.24A) and 14 weeks after injection ( Fig. 24B ) in plasma, and FD802-5 showed a dose-dependent effect.

[0073] Fig.25 It was shown that injection of a medium dose of FD802-5 had no observable negative effects on the liver relative to untreated Fabry mice and Fabry mice treated with a medium dose of FD802-3. DETAILED DESCRIPTION

[0074] Provided herein are compositions useful for treating Fabry disease and / or alleviating the symptoms of Fabry disease.

[0075] Currently, regular infusion of recombinant α-GAL A, i.e., enzyme replacement therapy (ERT), is the main treatment option for Fabry patients with non-susceptible mutations, while patients with susceptible mutations can benefit from ERT and treatment with small molecule chaperones. However, recombinant α-GAL A has low physical stability, short circulation half-life, and variable uptake by different disease-related tissues, which may limit the efficacy of ERT. The compositions provided herein deliver nucleotide sequences encoding recombinant α-GAL A, which are effective for gene therapy and have a longer duration of circulating enzyme activity before α-GAL A is absorbed into the targeted tissue.

[0076] In certain embodiments, the compositions and methods described herein include nucleotide sequences, expression cassettes, vectors, recombinant viruses, peptide sequences, engineered peptides, and other compositions and methods for expressing functional α-GAL A. In certain embodiments, the compositions and methods described herein include nucleotide sequences, expression cassettes, vectors, recombinant viruses, peptide sequences, engineered peptides, host cells, and compositions and methods for producing any nucleotide sequence encoding functional α-GAL A. In further embodiments, the compositions and methods described herein include nucleotide sequences, expression cassettes, vectors, recombinant viruses, peptide sequences, engineered peptides, and other compositions and methods for delivering nucleotide sequences encoding functional α-GAL A to a subject to treat Fabry disease. In one embodiment, the compositions and methods described herein can be used to provide therapeutic levels of functional α-GAL A in the periphery, such as in the blood, liver, kidneys, and / or peripheral nervous system of a subject. In certain embodiments, the adeno-associated virus (AAV) vector-based methods described herein provide a new treatment option that helps to restore the desired function of α-GAL and alleviate symptoms associated with α-GAL deficiency and / or dysfunction (Fabry disease) by providing expression of functional α-GAL A in subjects in need.

[0077] As shown in the Examples section, several heterologous signal peptides (sp1-sp22) were screened in vitro to obtain equivalent or superior extracellular secretion of α-GAL A, and compared with wt sp, sp1, 3, 4, 18 and 20-22 showed higher extracellular secretion levels (Example 1, Figure 2A and 2B ). Human sp21 was selected as an example of heterologous sp to construct an rAAV vector, wherein the rAAV vector comprises a nucleotide sequence encoding α-GAL A fused with the heterologous sp ( Figure 1A and 1B , vectors ss-sp21GLA, FD802-2, and FD802-4) to express α-GAL A fused to wt sp in rAAV vectors ( Figure 1A and 1B , vectors ss-wtspGLA, FD802-1 and FD802-3) were compared. Fabry mice were treated with rAAV vectors to compare the expression and activity of α-GAL A and the clearance rate of lyso-Gb3 in plasma, various organs and / or tissues. The data show that in various embodiments, heterologous sp such as sp21 is superior to wt sp in the expression and secretion of α-GAL A and the clearance of lyso-Gb3 without interfering with tissue structure. Examples 1-3 tested rAAV vectors containing wt hGLA and nucleotide sequences encoding sp (wt sp or sp21) in Fabry mice, and the sp21 group showed higher α-GAL A expression and activity in plasma, liver, heart, kidney and spleen, as well as higher plasma lyso-Gb3 clearance, while gaining less weight. Example 4-5 rAAV vectors containing optimized hGLA nucleotide sequence (hGLA cov1) and sp nucleotide sequence (wt-sp, wtSPc.o. or SP21) were tested in Fabry mice. Compared with the corresponding wt hGLA group, the hGLA cov1 group had a higher level of plasma ( Fig.12 ), liver, heart, kidneys, and spleen ( Fig.13 ) showed higher α-GAL A expression and activity, as well as higher plasma lyso-Gb3 clearance (17A and 17B). Example 6 shows that, in addition to AAV8, rAAVs of various serotypes constructed by FD802-4 vectors containing hGLA cov1 and SP21 can successfully express α-GAL A ( Fig.19A and 19B). Examples 7 and 8 tested rAAV vectors comprising functional variants of hGLAc.ov1 and wtSP nucleotides (wtSP co) and with or without nucleotide sequences encoding TAT p47-57 (tat). When administered to Fabry mice at 5E+12 vg / kg, the rAAV vector comprising hGLA cov1, wtSP co and tat (FD802-5) showed higher α-GAL A activity in the heart and spleen, but not in the liver, kidney ( Fig. 21B ) and plasma ( Fig.21A ) showed lower α-GAL A activity. Higher α-GAL A protein levels were observed in the hearts of Fabry mice injected with FD802-5 compared with Fabry mice injected with FD802-3 ( Fig. 22 In the liver of Fabry mice, the fusion protein of TAT p47-57 and α-GAL A did not produce changes in expression and glycosylation ( Fig.23A -B). The vector expressing α-GAL A fused to TAT p47-57 (FD802-5) also showed effective lyso-Gb3 clearance ( Fig.24A -B), and no negative effects were observed in the liver tissue of Fabry mice ( Fig.25 ).

[0078] definition

[0079] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this technology belongs. For the purposes of this technology, the following terms will be defined.

[0080] The articles "a" and "an" are used herein to refer to one or more grammatical objects (i.e., at least one) of the article. For example, "an element" refers to one element or a plurality of elements. Likewise, any reference to the singular includes plural embodiments, and any reference to more than one component may include a singular embodiment.

[0081] The term "about" refers to an amount, level, value, quantity, frequency, percentage, dimension, size, amount, weight, or length that varies according to acceptable levels in the art. In some embodiments, the variation may be as much as 30%, 25%, 20%, 15%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, or 1% of the reference amount, level, value, quantity, frequency, percentage, dimension, size, amount, weight, or length. When the term "about" is used with a numerical range, it modifies the range by extending the boundaries above and below the listed values.

[0082] As used herein, the term "therapeutic level" or "therapeutically effective" of functional α-GAL A refers to at least about 5%, about 10%, about 20%, about 25%, about 30%, about 35%, about 40%, about 45%, about 50%, about 55%, about 60%, about 65%, about 70%, about 75%, about 80%, about 85%, about 90%, about 95%, about 100%, greater than 100%, about 2-fold, about 3-fold, or about 5-fold the enzyme activity of a healthy control. Suitable assays for measuring α-GAL A enzyme activity are known to those of skill in the art. In some embodiments, such therapeutic levels of α-GAL A can result in a reduction in symptoms associated with Fabry disease, an improvement in disease biomarkers associated with Fabry disease (e.g., a decrease in Gb3 levels in serum, urine, and / or other biological samples), promotion of other treatments for Fabry disease (e.g., enzyme replacement or companion therapy), prevention of neurocognitive decline, reversal of some Fabry disease-associated symptoms, and / or prevention of progression of symptoms associated with Fabry disease, or any combination thereof.

[0083] As used herein, "healthy control" refers to a subject or biological sample thereof, wherein the subject does not have Fabry disease or α-GAL A deficiency and / or dysfunction. A healthy control can be from one subject. In another embodiment, a healthy control is a pooled sample from multiple subjects.

[0084] As used herein, the term "biological sample" refers to any cell, biological fluid or tissue. Suitable samples for the present invention may include, but are not limited to, whole blood, leukocytes, fibroblasts, serum, urine, plasma, saliva, bone marrow, cerebrospinal fluid, amniotic fluid and skin cells. Such samples may be further diluted with physiological saline, buffer or a physiologically acceptable diluent. Alternatively, these samples may be concentrated by conventional methods.

[0085] Each of the vectors and other compositions described herein is useful in another embodiment. In addition, each composition described herein that is useful in the methods can be an embodiment of the invention.

[0086] As used herein, "disease," "disorder," and "symptom" refer to Fabry disease and / or α-GAL A deficiency and / or dysfunction in a subject.

[0087] As used herein, "engineering" refers to constructing a peptide or vector comprising a specific peptide or genetic element, such as a specific nucleotide sequence to produce a specific protein product. "Engineering" also includes manipulating endogenous and exogenous genetic elements or peptide elements to produce a desired product, nucleic acid or protein sequence and / or construct.

[0088] As used herein, "portion" refers to at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% of the nucleotide sequence or amino acid sequence of the full-size genetic element or peptide. For example, a portion of the hGLA nucleotide sequence comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% of the nucleotide sequence of the complete hGLA nucleotide sequence. Another example is a portion of α-GAL A that comprises at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% of the amino acid sequence of the complete α-GAL A.

[0089] As used herein, "wild type," "wt," and "endogenous" are used interchangeably to describe a naturally occurring or native gene, protein, nucleotide sequence, or peptide sequence.

[0090] As used herein, "heterologous" is used to describe a gene, protein, nucleotide sequence, or peptide sequence that is not naturally occurring or exogenous.

[0091] As used herein, "nucleic acid" refers to a polymeric form of nucleotides, including RNA, mRNA, cDNA, genomic DNA, peptide nucleic acid (PNA), and synthetic forms and mixed polymers of the above. Nucleotide refers to a ribonucleotide, a deoxynucleotide, or a modified form of any nucleotide (e.g., a peptide nucleic acid oligomer). The term also includes single-stranded and double-stranded forms of DNA. The above are functional variants of these nucleic acid molecules. Functional variants refer to a nucleotide sequence that, when directly translated using the standard genetic code, produces the same amino acid sequence as translated from the parent nucleic acid molecule.

[0092] In certain embodiments, nucleic acid molecules encoding functional α-GAL A and other structures described herein can be used to generate expression cassettes and vector genomes, and can be engineered for expression in yeast cells, insect cells or mammalian cells (e.g., human cells). Methods are known and have been described previously, such as the methods described in WIPO Patent Application Publication No. WO 1996 / 09378, which is incorporated herein by reference in its entirety. If at least one non-preferred codon is replaced by a more preferred codon compared to the wt sequence, the nucleotide sequence is considered to be engineered. Here, a non-preferred codon refers to a codon that is used less frequently in an organism than another codon encoding the same amino acid, and a more preferred codon refers to a codon that is used more frequently in an organism than a non-preferred codon. The frequency of codon usage for a particular organism can be found in a codon frequency table, such as www.kazusa.jp / don. Preferably, more than one non-preferred codon, preferably most or all non-preferred codons, are replaced by more preferred codons. Preferably, the most commonly used codons in an organism are used in the engineered nucleotide sequence, and replacement with a preferred codon generally results in higher expression. The skilled person will also understand that due to the degeneracy of the genetic code, many different nucleic acid molecules can encode the same polypeptide. The skilled person can express the polypeptide by replacing nucleotides according to the codon usage of any host organism without affecting the encoded amino acid sequence. Therefore, unless otherwise specified, "nucleic acid sequence encoding an amino acid sequence" and "nucleotide sequence encoding an amino acid sequence" include all nucleotide degenerate sequences of the two, as well as all nucleotide sequences encoding the same amino acid sequence. Nucleotide sequences can be cloned using conventional molecular biology techniques, or produced by DNA synthesis, which can also be done by companies that provide DNA synthesis and / or molecular cloning services (such as GeneArt, GenScript, Life Technologies, Eurofins) using conventional procedures.

[0093] In certain embodiments, the nucleic acids, expression cassettes, and vector genomes described herein include engineered α-GAL A encoding nucleotide sequences. In certain embodiments, the engineered sequences can improve safety during production, transcription, expression, or use in subjects. In certain embodiments, the engineered sequences can be used to improve the efficacy of the resulting therapeutic composition or treatment. In further embodiments, the engineered nucleotide sequences can be used to improve the efficacy of the expressed functional α-GAL A, and therapeutic efficacy can be produced at a lower dose of a therapeutic agent encoding functional α-GAL A. In certain embodiments, the engineered hGLA nucleic acid encoding sequence is characterized by an increased translation rate compared to the wild-type hGLA nucleotide encoding sequence. The so-called "engineering" refers to assembling and placing the functional α-GAL A encoding nucleotide sequence described herein into any suitable genetic element (such as naked DNA, bacteriophage, transposon, cosmid, episome, etc.), and being carried and transferred to a host cell for the production of a non-viral delivery system (such as an RNA-based system, naked DNA, etc.), a viral vector, and / or a host cell for delivery to a subject. In certain embodiments, the genetic element is a vector. In one embodiment, the genetic element is a plasmid. Methods for making such engineered structures are known to those skilled in the art of nucleic acid manipulation, and include genetic engineering, recombinant engineering, and synthetic techniques. See: Green, Sambrook. Molecular Cloning: A Laboratory Manual. New York: Cold Spring Habor Press, (2012).

[0094] In the context of nucleotide sequences, the terms "percent (%) identity", "sequence identity", "percent sequence identity" or "identical percentage" refer to the residues in the two sequences that are identical when two nucleotide sequences are aligned for correspondence. The length of the sequence identity comparison can be the full length of the structure, the full length of the gene encoding nucleotide sequence, or a fragment of at least about 500 to 1000 nucleotides. However, identity between smaller fragments may also be desired, such as fragments containing at least about 9 nucleotides, generally at least about 20 to 24 nucleotides, at least about 28 to 32 nucleotides, or at least about 36 or more nucleotides.

[0095] The percent identity of a full-length protein, a polypeptide, about 100 amino acids, about 300 amino acids, a peptide fragment, or a peptide segment encoded by a nucleotide sequence is readily determined. Suitable amino acid fragments may be at least about 8 amino acids in length, and may be up to about 50 amino acids in length. Generally, when referring to "identity," "homology," or "similarity" between two different amino acid sequences, "identity," "homology," or "similarity" is determined by the same amino acid sequence (identical sequence), i.e., a plurality of identical nucleotide or protein (amino acid) sequences when compared to a reference amino acid sequence, typically including corrected missing or added bases or amino acids.

[0096] Identity can be determined by comparing amino acid sequences using various algorithms and / or computer programs known or commercialized in the art (e.g., BLAST, ExPASy, Clustal Omega, FASTA, Needleman-Wunsch algorithm, Smith-Waterman algorithm). Any public or commercial multiple sequence alignment program can be used to determine identical sequences. Sequence alignment programs can be used to align amino acid sequences, such as "Clustal Omega", "Clustar X", "MAP", "PIMA", "MSA", "BLOCKMAKER", "MEME" and "Match Box" programs. These programs are usually used under default settings, but those skilled in the art can also change the settings as needed. Those skilled in the art can also use other algorithms or computer programs that provide a level of identity or identical sequence that is not less than that provided by the cited algorithms and programs. See, e.g., JD Thomson et al, Nucl. Acids. Res., A comprehensive comparison of multiple sequence alignments," 27(13): 2682-2690 (1999).

[0097] As used herein, the terms "human GLA", "hGLA" and "GLA" are interchangeable when used to refer to a therapeutic gene encoding mature α-GAL A or a functional variant thereof. The Greek letter "alpha" and the symbol "α" are used interchangeably in this specification. Examples of hGLA include, but are not limited to, natural (wild-type) hGLA encoding mature α-GAL A, functional variants of wt-hGLA, and optimized nucleotide sequences thereof (e.g., hGLA cov1). In certain embodiments, hGLA comprises or consists of SEQ ID NO: 25. In certain aspects, hGLA comprises or consists of a nucleotide sequence having at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 25. In certain aspects, hGLA comprises or consists of a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 25. In certain aspects, hGLA comprises or consists of a nucleotide sequence that is about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 25. In certain embodiments, hGLA comprises or consists of SEQ ID NO: 26. In certain aspects, hGLA comprises or consists of a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26. In certain aspects, hGLA comprises or consists of a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26. In certain aspects, hGLA comprises or consists of a nucleotide sequence that is about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26.

[0098] As used herein, the term "α-GAL A" refers to human α-galactosidase A protein or therapeutic peptide. Alternative names for α-galactosidase A include galactosidase α, α-D-galactosidase A, α-galactosidase A protein, α-galactosidase A enzyme, α-D-galactosyl galactohydrolase, α-galactosidase, α-galactosidase A, ceramide trihexosidase, GALA, α-GAL A, galactosidase, α-galactosidase, and melibiase. The Greek letter "alpha" and the symbol "α" are used interchangeably in this specification. Examples of α-GAL A include, but are not limited to, naturally occurring (wild-type) α-GAL A, particularly variants of α-GAL A expressed by the nucleotide sequences provided herein, or functional fragments that can restore desired function, improve symptoms, improve symptoms associated with Fabry disease-associated biomarkers (e.g., serum α-GAL), and / or facilitate other treatments for Fabry disease when delivered in the compositions provided herein or by the methods provided herein.

[0099] Unless otherwise indicated, "α-GAL A" refers to the mature protein after the signal peptide is cleaved, the variant protein described herein, or a functional fragment thereof. As used herein, the term "functional α-GAL A" refers to a peptide having an amino acid sequence of a full-length native (wild-type) protein (as shown in UniProtKB Accession No.: P06280-1), a variant thereof (including a variant with a specific amino acid substitution described herein), a fragment thereof, a full-length or fragment thereof, any combination of variants and mutants thereof, etc., which can provide at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, about the same, or higher than the biological activity level of the native (wild-type) α-GAL A. In some embodiments, α-GAL A is encoded by a nucleotide sequence comprising or consisting of SEQ ID NO: 25. In some aspects, α-GAL A is encoded by a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 25. In some aspects, α-GAL A is encoded by a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 25. In some aspects, α-GAL A is encoded by a nucleotide sequence that is about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 25. In some embodiments, α-GAL A is encoded by comprising or by the nucleotide sequence SEQ ID NO: 26. In some aspects, α-GAL A is encoded by a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26. In certain aspects, α-GAL A is encoded by a nucleotide sequence that is at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26. In certain aspects, α-GAL A is encoded by a nucleotide sequence that is about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99%, or 100% identical to SEQ ID NO: 26.

[0100] As used herein, "functional variant" refers to a protein or nucleotide variant (including peptides or nucleotides with specific amino acid and nucleotide substitutions described herein), a protein or nucleotide mutant with conservative amino acid or nucleotide substitutions, a protein or nucleotide fragment, a full length or fragment of any combination of variants and mutants with conservative amino acid or nucleotide substitutions, etc., that can provide at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 65%, at least about 70%, at least about 75%, at least about 80%, at least about 90%, about the same, or about higher than the level of biological activity or expression ability of a peptide (e.g., wt α-GAL A) or nucleotide sequence (e.g., wt hGLA).

[0101] As used herein, "signal peptide" or "sp" refers to a peptide sequence fused to or within a therapeutic peptide that can affect the function or localization of a therapeutic peptide. The signal peptide (sp) can be fused to the N-terminus of the therapeutic peptide or placed near the N-terminus, fused to the C-terminus of the therapeutic peptide or placed near the C-terminus, inside the therapeutic peptide, or any combination of the foregoing. sp may be a wild-type or naturally occurring heterologous signal peptide. sp (lowercase letters) refers to a signal peptide or a functional variant thereof, and sp (uppercase letters) refers to a nucleotide sequence encoding a signal peptide or a functional variant thereof. The nucleotide sequence encoding sp may be referred to as sp. The signal peptide referred to by sp may be one of the wt sp or heterologous sp disclosed herein, and the nucleotide sequence sp encoding the signal peptide may be a nucleotide sequence encoding a wt sp or a heterologous sp.

[0102] As used herein, "tissue-specific promoter" refers to a genetic element that causes a peptide sequence to be expressed in a specific tissue. A tissue-specific promoter can cause a peptide sequence to be expressed in one or more tissues.

[0103] As used herein, "vector" refers to a nucleotide sequence that introduces an exogenous or engineered nucleotide sequence into a cell. A vector can be linear or circular. A vector can be, for example, a plasmid, a virus, a phage, or a cosmid. The vector can contain one or more expression cassettes. The vector can be engineered.

[0104] As used herein, "viral vector" refers to a vector that uses a viral genome to deliver genetic material to a cell. The viral genome can be modified to include or delete genetic elements. Viral vectors can be designed or synthesized in vivo or in vitro. Viral vectors can be retroviruses, lentiviruses, poxviruses, adenoviruses, and adeno-associated viruses. Viral vectors can be single-stranded or self-complementary structures, such as ss-rAAV or sc-rAAV.

[0105] As used herein, "serotype" refers to biologically distinguishing characteristics of a particle and / or variants thereof, such as surface antigens. The serotype may be selected from at least one of rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV12, rAAV13, and any derivatives thereof, such as a serotype engineered using directed evolution.

[0106] As used herein, "cell-penetrating peptide" refers to a peptide, protein, or protein fragment that can pass through a cell or organelle membrane or has the ability to transport through a cell or organelle membrane. The cell-penetrating peptide can be fused to the N-terminus of a therapeutic peptide or placed near the N-terminus, fused to the C-terminus of a therapeutic peptide or placed near the C-terminus, inside a therapeutic peptide, or any combination of the foregoing.

[0107] As used herein, "encapsulation" and "encapsulation" refer to packaging, fixing or enclosing a carrier with structural proteins and / or lipid molecules.

[0108] As used herein, "Gb3" refers to sphingolipids, globulin, or triglycosylceramide. Gb3 may also be referred to as "Gls" or "GL3". Gb3 may be a free sphingolipid or may be bound to different molecules or cell membranes. Gb3 may also refer to an acetylated derivative of Gb3 or acetylated Lyso-Gb3.

[0109] As used herein, "lyso-Gb3" refers to a deacetylated derivative of Gb3. Lyso-Gb3 also refers to a plasma biomarker for Fabry disease. Lyso-Gb3 may be referred to as "lyso-Gls" or "lyso-GL3".

[0110] As used herein, "patient" or "subject" refers to a male or female mammal, such as a human, dog, animal model, used in clinical studies. In certain embodiments, the subject of the methods and compositions is a human diagnosed with Fabry disease. In further embodiments, the human subject of the methods and compositions is a prenatal, newborn, infant, toddler, preschooler, elementary school age child, adolescent, young adult, or adult.

[0111] As used herein, "sphingolipid storage" refers to processes involving the anabolism and catabolism of sphingolipids and the distribution of sphingolipids in leukocytes and tissues (including but not limited to bone marrow, skin, muscle). Sphingolipid storage may also indicate the activity of α-GAL A. Sphingolipid storage diseases may refer to α-GAL A deficiency or dysfunction, or deficiency of enzymes involved in sphingolipid metabolism.

[0112] As used herein, the terms "Fabry disease," "Fabry-related symptoms," or "symptoms" refer to symptoms found in patients with Fabry disease or in animal models of Fabry disease. Such symptoms include, but are not limited to, angiokeratomas, paresthesias in the extremities, hypohidrosis / anhidrosis, corneal opacities, lens opacities, cardiac problems, pain, and decreased renal function. In addition, common cardiac-related signs and symptoms of Fabry disease include left ventricular hypertrophy, valvular disease (especially mitral valve prolapse and / or regurgitation), premature coronary artery disease, angina, myocardial infarction, cardiac conduction abnormalities, arrhythmias, and congestive heart failure. Other names for Fabry disease include alpha-galactosidase A deficiency, Anderson-Fabry disease, and refractory angiokeratomas.

[0113] As used herein, "Fabry mouse" refers to a mouse model lacking α-GAL A, which can be used as a model of Fabry disease. For example, the case reported is doi:10.1073 / pnas.94.6.2540, see Proc Natl Acad Sci US A. 1997 Mar 18; 94(6):2540-42540-4.

[0114] As used herein, "administering" or "administration" refers to delivering a therapy or composition of the present technology to a subject by topical or systemic administration. It can be intratracheal, intranasal, epidermal, transdermal, oral or parenteral administration. Parenteral administration includes intravenous, intraarterial, subcutaneous, intraperitoneal or intramuscular injection or infusion, or intracranial administration such as intrathecal or intraventricular administration.

[0115] As used herein, "therapeutically effective amount" refers to the amount that produces the desired effect on the subject's indication, condition, disease or illness. In certain embodiments, the therapeutically effective amount is the amount that produces the maximum therapeutic effect. In other embodiments, the therapeutic effect produced by the therapeutically effective amount is less than the maximum therapeutic effect. For example, the therapeutically effective amount can be the amount that produces the therapeutic effect while avoiding one or more side effects associated with the dose that produces the maximum therapeutic effect. The therapeutically effective amount of a particular composition will vary based on a variety of factors, including but not limited to the characteristics of the therapeutic composition (such as activity, pharmacokinetics, pharmacodynamics and bioavailability), the subject's physiological condition (such as age, weight, sex, disease type and stage, medical history, general physical condition, responsiveness to a given dose and other drugs in use), any pharmaceutically acceptable carriers, excipients and preservatives in the composition, and the route of administration. Technicians in the clinical and pharmacological fields can determine the therapeutically effective amount by routine experiments, i.e., by monitoring the subject's response to the administration of the therapeutic composition and adjusting the dosage accordingly.

[0116] As used herein, "clinically effective amount", "clinically effective concentration", "clinically effective dose" refers to a concentration or dose of a peptide, composition or pharmaceutical composition that has been shown to be effective in a clinical trial or predicted to be effective based on an early or preclinical trial. In some embodiments, a "clinically effective amount" is the same as a "therapeutically effective amount". In some embodiments, a "clinically effective amount" is higher or lower than a "therapeutically effective amount". For other guidance, see Remington: The Science and Practice of Pharmacy, 21st Edition, Univ. of Sciences in Philadelphia (USIP), Lippincott Williams & Wilkins, Philadelphia, PA, 2005.

[0117] Engineered Peptides

[0118] Described herein are engineered peptides designed to deliver α-GAL A to desired cells or subjects. α-GAL A catalyzes the hydrolysis of sphingolipids and participates in the degradation of sphingolipids in lysosomes. When α-GAL A is absent or dysfunctional, sphingolipids such as glycosphingolipids and their byproducts may accumulate to harmful levels. This accumulation and α-GAL A deficiency are common in patients with Fabry disease. Seeking methods to promote increased α-GAL A activity can be used for the treatment of Fabry disease. Delivery of α-GAL A to a subject via an engineered peptide is a potential treatment method. Restoring α-GAL A levels using an engineered peptide can promote metabolic homeostasis, especially sphingolipid metabolism. Further modification of the engineered peptide comprising α-GAL A can improve the efficiency, targeting, and stability of the peptide. Such modifications can include altering the wt α-GAL A amino acid sequence to produce a functional variant to more effectively restore the function of α-GAL.

[0119] In some embodiments, α-GAL A is human α-GAL A. In some embodiments, the engineered peptide comprises α-GAL or a functional variant thereof. In some embodiments, the engineered peptide further comprises one or more signal peptides or functional variants thereof, and optionally one or more cell-penetrating peptides or functional variants thereof. One or more signal peptides or functional variants thereof and one or more cell-penetrating peptides or functional variants thereof can be fused to the C and / or N-terminus, near the C and / or N-terminus, and / or within the sequence of α-GAL A or its functional variant. In certain embodiments, the engineered peptide comprises a spacer sequence between α-GALA or its functional variant and one or more signal peptides or functional variants. In certain embodiments, the engineered peptide comprises a spacer sequence between α-GAL A or its functional variant and one or more cell-penetrating peptides or functional variants. In certain embodiments, the engineered peptide comprises at least one signal peptide fused near the N-terminus or N-terminus of α-GAL A or its functional variant. In certain embodiments, the engineered peptide comprises a plurality of signal peptides. A plurality of signal peptides can be fused sequentially at the N-terminus. In certain embodiments, the engineered peptide comprises a plurality of cell-penetrating peptides. Multiple cell-penetrating peptides can be fused sequentially to any site of the protein.

[0120] In certain aspects, human α-GAL A is encoded by wt-hGLA (SEQ ID NO: 25). In certain aspects, human α-GAL A is encoded by a functional variant of the wt nucleotide sequence. In certain aspects, the functional variant is hGLA cov1 (SEQ ID NO: 26).

[0121] In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A comprising a peptide sequence having at least about 60% to 100% identity to SEQ ID NO: 27. In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A having a peptide sequence having at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 27.

[0122] In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A having a peptide sequence at least about 60% to 100% identical to SEQ ID NO: 27. In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A having a peptide sequence at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 27.

[0123] In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A having a peptide sequence at least about 60% to 100% identical to SEQ ID NO: 27. In some embodiments, the engineered peptide comprises α-GAL A or a functional variant of α-GAL A having a peptide sequence about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to SEQ ID NO: 27.

[0124] Table 1: Amino acid sequence of α-GAL A and nucleotide sequence encoding α-GAL.

[0125]

[0126]

[0127]

[0128] Signal peptide

[0129] Engineered peptides comprising α-GAL A can be further modified to improve the efficiency, targeting and stability of the peptide. Such modifications may include changing the signal peptide sequence to more effectively restore α-GAL A function. Signal peptides are peptides that promote, target, locate and provide other signal queues for therapeutic peptide transport. Functional variants are peptides that promote targeting and positioning. Signal peptides (sp) can be signal sequences, targeting signals, localization signals, localization sequences, transit peptides, leader sequences or leader peptides. Engineered peptides may include endogenous or engineered sp. Engineered peptides may have more than one sp. Including, deleting, changing, replacing or editing sp can change protein function. The position of sp can also affect activity. In addition, sp sequences can be modified or synthesized to improve protein function, abundance or activity. In the present technology, incorporating different sps into engineered peptide sequences can enhance the delivery, secretion and / or overall efficacy of α-GAL A of engineered peptides.

[0130] In some embodiments, the engineered peptide comprises a signal peptide or a functional variant thereof. In some embodiments, sp or a functional variant thereof is fused to the N-terminus or near the N-terminus of the α-GAL A portion or its functional variant. In some aspects, sp or a functional variant thereof is fused to the C-terminus or near the C-terminus of α-GAL A or its functional variant. In some aspects, sp or a functional variant thereof is located inside α-GAL A or its functional mutant.

[0131] In some embodiments, the engineered peptide comprises endogenous human α-GAL A wt sp (SEQ ID NO: 28) or a functional variant thereof.

[0132] In some embodiments, the engineered peptide comprises a heterologous signal peptide or a functional variant thereof.

[0133] In some embodiments, the engineered peptide comprises a wt sp or a functional variant thereof, and a heterologous sp or a functional variant thereof. In some embodiments, the engineered peptide comprises two or more heterologous sp or their functional variants.

[0134] In certain aspects, the one or more heterologous signal peptides are selected from sp1, sp2, ... and sp22, whose amino acid sequences are provided in Table 2. In certain embodiments, the one or more heterologous signal peptides are selected from sp1, sp3, sp4, sp18, sp20, sp21 and sp22.

[0135] In some aspects, wt sp or a functional variant thereof is encoded by a nucleotide sequence having at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51. In some aspects, wt sp or a functional variant thereof is encoded by a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51. In some aspects, wt-sp or a functional variant thereof is encoded by a nucleotide sequence having about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51.

[0136] In certain embodiments, the one or more heterologous signal peptides or functional variants thereof are encoded by one or more nucleotide sequences, which are at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to one or more nucleotide sequences selected from SEQ ID NO: 2, 3, 4, ... and 23 listed in Table 2. In certain aspects, the one or more heterologous signal peptides or functional variants thereof are encoded by one or more nucleotide sequences, which are at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to one or more nucleotide sequences selected from SEQ ID NO: 2, 3, 4, ... and 23 listed in Table 2. In certain aspects, the one or more heterologous signal peptides or functional variants thereof are encoded by one or more nucleotide sequences, which have about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity with one or more nucleotide sequences selected from SEQ ID NO: 2, 3, ... and 23 listed in Table 2.

[0137] Table 2: Endogenous human α-GAL A wt sp, heterologous sp, and nucleotide sequences encoding wt sp and heterologous sp.

[0138]

[0139]

[0140] In some embodiments, the nucleotide sequence encoding sp comprises or consists of SEQ ID NO: 1 or 51. In some aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51. In some aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51. In some aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 1 or 51. In certain embodiments, sp is sp21. In some embodiments, the nucleotide sequence encoding sp comprises or consists of SEQ ID NO: 22. In some aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 22. In certain aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 22. In certain aspects, the nucleotide sequence encoding sp comprises or consists of a sequence having about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 22.

[0141] Cell Penetrating Peptides

[0142] As mentioned above, further modification of the engineered peptides comprising α-GAL A can improve the efficiency, targeting and stability of the peptides. The modification can be to include or change the cell-penetrating peptide sequence. The cell-penetrating peptide can help expand the molecular delivery and peptide transport of the cell or organelle membrane. The cell-penetrating peptide sequence or its functional variant is included in the engineered peptide sequence to promote the delivery and / or secretion of the peptide. The position of the cell-penetrating peptide in the peptide sequence can also affect the delivery and / or secretion of the peptide. The engineered peptide can be included in the cell-penetrating peptide. In this article, the TAT sequence is included in the engineered peptide. The TAT sequence may include an arginine-rich sequence that directly penetrates the cell or organelle membrane. In the present technology, the delivery, secretion and / or overall efficacy of the α-GAL A of the engineered peptide can be enhanced by including TAT or other cell-penetrating peptides in the engineered peptide sequence. Examples of cell penetrating peptides include, but are not limited to, TATp47-57, TAT p48-60, penetratin p43-58, hCT p-9-32, polyarginine, pVEC, Pep-1, transportin, and MAP.

[0143] In some aspects, the present technology describes an engineered peptide comprising α-GAL A and a cell-penetrating peptide, which can be incorporated into an engineered peptide sequence to regulate, including but not limited to, peptide properties that enhance peptide secretion and delivery to target cells or tissues. In some embodiments, the engineered peptide includes a cell-penetrating peptide or a functional variant thereof. In some embodiments, the cell-penetrating peptide includes or is at least composed of TAT p47-57 (SEQ ID NO: 55) or a functional variant thereof. In some aspects, the cell-penetrating peptide is encoded by a nucleotide sequence with at least about 60-100% identity to SEQ ID NO: 24. In some aspects, the cell-penetrating peptide is encoded by a nucleotide sequence with at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 24.

[0144] In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having at least 60-100% identity to SEQ ID NO: 24. In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 24.

[0145] In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having about 60-100% identity to SEQ ID NO: 24. In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having about 80%, 60%, 65%, 70%, 75%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO: 24.

[0146] In some embodiments, the cell-penetrating peptide comprises or consists of at least an amino acid sequence selected from TAT p47-57 (SEQ ID NO: 55), TAT p48-60 (SEQ ID NO: 56), penetrant p43-58 (SEQ ID NO: 57), hCT p9-32 (SEQ ID NO: 58), polyarginine (SEQ ID NO: 59), pVEC (SEQ ID NO: 60), Pep-1 (SEQ ID NO: 61), transporter (SEQ ID NO: 62), MAP (SEQ ID NO: 63) or a functional variant thereof. In certain aspects, the cell-penetrating peptide is encoded by a nucleotide sequence having at least about 60-100% identity with a nucleotide sequence selected from SEQ ID NO: 24, 52, 53 and 54. In certain aspects, the cell penetrating peptide is encoded by a nucleotide sequence that is at least about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identical to a nucleotide sequence selected from SEQ ID NOs: 24, 52, 53 and 54.

[0147] In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having at least 60-100% identity with a nucleotide sequence selected from SEQ ID NOs: 24, 52, 53, and 54. In some aspects, the cell penetrating peptide is encoded by a nucleotide sequence having at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity with a nucleotide sequence selected from SEQ ID NOs: 24, 52, 53.

[0148] In some aspects, the cell-penetrating peptide is encoded by a nucleotide sequence having about 60-100% identity with a nucleotide sequence selected from SEQ ID NOs: 24, 52, 53, and 54. In some aspects, the cell-penetrating peptide is encoded by a nucleotide sequence having about 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 99% or 100% identity with a nucleotide sequence selected from SEQ ID NOs: 24, 52, 53.

[0149] In some embodiments, the cell penetrating peptide is fused to the C-terminus of α-GAL A. In some aspects, the cell penetrating peptide is fused to the N-terminus of α-GAL A.

[0150] In some aspects, the engineered peptide includes more than one cell-penetrating peptide or functional variant thereof. In some aspects, the engineered peptide comprises a first cell-penetrating peptide or functional variant thereof fused to the N-terminus or near the N-terminus of α-GAL A, and a second cell-penetrating peptide or functional variant thereof fused to the C-terminus or near the C-terminus of α-GAL A. In some aspects, the engineered peptide comprises a first cell-penetrating peptide or functional variant thereof fused to the N-terminus or near the N-terminus of α-GAL A, and a second cell-penetrating peptide or functional mutant thereof placed inside α-GAL. In some aspects, the engineered peptide comprises a first cell-penetrating peptide or functional variant thereof fused to the C-terminus or near the C-terminus of α-GAL A, and a second cell-penetrating peptide or functional mutant thereof placed inside α-GAL.

[0151] In some aspects, the engineered peptide includes a first cell-penetrating peptide or a functional variant thereof fused to the N-terminus or near the N-terminus of α-GAL A, a second cell-penetrating peptide or a functional variant thereof fused to the C-terminus or near the C-terminus of α-GAL A, and a third cell-penetrating peptide or a functional mutant thereof placed inside α-GAL.

[0152] Table 3: Cell penetrating peptides and nucleotide sequences encoding cell penetrating peptides

[0153]

[0154] Viral vectors

[0155] Treatment methods that promote increased α-GAL A activity can be used to treat Fabry disease. One potential treatment method is to deliver α-GAL A to a subject via a viral vector expressing an engineered peptide. The constructed viral vector can deliver genetic material and express the engineered peptide in the desired cells or tissues of the subject. The viral genome can be modified to include or delete genetic elements. The expression cassette contains a nucleotide sequence that can express a protein and is one such genetic element. The viral vector can be a retrovirus, a lentivirus, a poxvirus, an adenovirus, and an adeno-associated virus, and can be designed and synthesized in vivo or in vitro. The present technology includes an rAAV vector comprising an rAAV genome, wherein the rAAV genome includes a nucleotide sequence encoding an engineered peptide of α-GAL A. The viral vector can be a single-stranded or self-complementary structure, referred to as ss-rAAV or sc-rAAV, respectively. In addition, the viral vector can be modified by encapsulation or serotype selection, each of which affects the efficacy of the viral vector. This article describes a method for promoting the expression and delivery of α-GAL A using a viral vector.

[0156] In some embodiments, the viral vector is encapsulated in a capsid. In some aspects, the viral vector comprises a serotype. In some aspects, the serotype is rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV12, or rAAV13. In some aspects, the serotype can be a derivative of rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV12, or rAAV13.

[0157] In some embodiments, the viral vector further comprises a promoter. In some aspects, the viral vector is a tissue-specific promoter. In some aspects, the viral vector is a liver, heart, kidney or spleen specific promoter. In some aspects, the liver-specific promoter is TTR, HBV, ALB, human alpha-1 antitrypsin (hAAT) or phosphoenolpyruvate carboxykinase (PEPCK) gene promoter. In some aspects, the liver-specific promoter is an engineered liver-specific promoter.

[0158] In some aspects, the viral vector comprises at least one ITR nucleotide sequence. In some aspects, the viral vector comprises a 5'ITR and a 3'ITR. In some aspects, the viral vector does not comprise any introns. In some aspects, the viral vector comprises at least one intron. In some aspects, the vector comprises a polyadenylation (polyA) nucleotide sequence. In some aspects, the viral vector comprises at least one ITR nucleotide sequence, an intron and / or a polyA nucleotide sequence. ss-rAAV and sc-rAA Figure 1A and 1B shown.

[0159] In some aspects, the viral vector comprises a 5'ITR, a 3'ITR, a tissue-specific promoter, an intron, a stop codon, a polyA nucleotide sequence, a hGLA nucleotide sequence, and a coding nucleotide sequence of sp. In certain embodiments, the hGLA nucleotide sequence is wt hGLA (SEQ ID NO: 25) or hGLA cov1 (SEQ ID NO: 26). In certain aspects, sp is wtsp or sp21. In certain aspects, the sp nucleotide sequence is the sp nucleotide sequence listed in Table 2. In certain aspects, the tissue-specific promoter is TTR. In certain aspects, the viral vector is a ss-rAAV vector or a sc-rAAV vector.

[0160] In some embodiments, the viral vector is rAAV8. In some aspects, the sc-rAAV vector is ss-wtspGLA or ss-sp21GLA. In some aspects, the ss-rAAV vector is FD802-1, FD802-2, FD802-3, FD802-4 or FD802-5.

[0161] In some aspects, the hGLA sequence is expressed by a viral vector. In some aspects, the vector comprising hGLA is ss-rAAV expressing α-GAL A+wt sp, ss-rAAV expressing α-GAL A+sp21, FD802-1 or FD802-2. In some aspects, the vector comprising hGLA cov1 (SEQ ID NO: 26) is FD802-3, FD802-4 or FD802-5.

[0162] In some aspects, the signal peptide is expressed by a viral vector. In some aspects, the vector expressing wt sp is ss-rAAV, FD802-1, FD802-3 or FD802-5 expressing α-GALA+wt sp. In some aspects, the vector expressing sp21 peptide is ss-rAAV, FD802-2 or FD802-4 expressing α-GAL A+sp21.

[0163] In some aspects, the cell-penetrating peptide is expressed from a viral vector. In some aspects, the vector expressing the cell-penetrating peptide is FD802-5.

[0164] Composition

[0165] The engineered peptides and viral vectors described herein can become pharmaceutical compositions, which contain, are mainly composed of or are entirely composed of an effective amount of one or more engineered peptides or viral vectors described herein. Modified compositions can achieve different ways of administration or improve the stability of the composition. In addition, the pharmaceutical composition can be modified to deliver different doses of active ingredients (such as engineered peptides, viral vectors and / or viral compositions). In some embodiments, the pharmaceutical composition further comprises one or more other non-engineered peptides or viral vectors described herein. In some embodiments, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier, excipient, additive, preservative, or a combination thereof. Acceptable carriers include physiologically acceptable solutions, such as sterile saline and sterile buffered saline.

[0166] In some embodiments, the engineered peptide is present in a pharmaceutical composition. In some embodiments, a viral vector is present in a pharmaceutical composition. In some aspects, an encapsulated vector is present in a pharmaceutical composition.

[0167] In some aspects, the pharmaceutical composition further comprises an excipient. In some aspects, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier. In some aspects, the pharmaceutical composition further comprises a pharmaceutically acceptable carrier and / or excipient. In some embodiments, the pharmaceutically acceptable carrier and / or excipient comprises water.

[0168] In some aspects, the pharmaceutical composition is administered intraperitoneally, intravenously, parenterally, subcutaneously, intramuscularly, intracerebroventricularly, or orally. In some embodiments, a single pharmaceutical composition is administered subcutaneously.

[0169] In some aspects, the pharmaceutical composition is administered with a second Fabry disease therapeutic agent.In certain aspects, the second Fabry disease therapeutic agent comprises an engineered peptide, a vector, or a viral vector.

[0170] Viral vectors can be formulated into pharmaceutical compositions or viral compositions to deliver genetic material to a desired subject for expression of a targeted peptide or therapeutic peptide. In some embodiments, the present technology provides a viral composition for increasing the expression of α-GAL A in a desired subject. In other embodiments, the present technology provides a viral composition for treating Fabry disease in a desired subject or alleviating the symptoms of Fabry disease. The expression cassette of the viral vector expresses α-GAL A, and the viral vector further comprises at least one ITR nucleotide sequence, intron and / or polyadenylation polyA nucleotide sequence. Modifying the viral composition can increase the expression of targeting peptides such as peptides comprising α-GAL A. Other factors that modify the viral composition can also improve the stability of the composition or the efficiency of delivery to target cells or tissues. These modifications include, but are not limited to, packaging of the viral vector to enhance delivery and stability, and selection of serotypes to allow specific targeted cell surface proteins to bind.

[0171] In some aspects, the viral composition comprises a viral vector expressing α-GAL A. In some aspects, the viral vector can be encapsulated. In some aspects, the viral vector is a rAAV vector. In some aspects, the viral vector is a sc-rAAV or ss-rAAV vector. In some aspects, the viral vector comprises serotype rAAV1, rAAV2, rAAV3, rAAV4, rAAV5, rAAV6, rAAV7, rAAV8, rAAV9, rAAV10, rAAV11, rAAV1 or rAAV13.

[0172] In some embodiments, the viral composition is for intraperitoneal, intravenous, parenteral, subcutaneous, intramuscular, intracerebroventricular, or oral administration. In some embodiments, a single pharmaceutical composition is for subcutaneous administration.

[0173] Related methods

[0174] The engineered peptides, viral vectors and pharmaceutical compositions described herein are intended for use in treating Fabry disease or alleviating symptoms associated with Fabry disease. Symptoms associated with Fabry disease include, but are not limited to, angiokeratomas, paresthesias of the acrofacial area, hypohidrosis / anhidrosis, corneal opacities, lens opacities, heart problems, pain, decreased renal function, or any symptoms caused by alpha-GAL A dysfunction or deficiency.

[0175] In some embodiments, the present technology provides a method for treating Fabry disease in a subject. In some embodiments, the present technology provides a method for reducing one or more symptoms associated with Fabry disease in a subject. In some embodiments, the present technology provides a method for increasing the expression of α-GAL A in a subject. In some aspects, the expression and / or activity of α-GAL in the target tissue and / or plasma of the subject is increased. In some aspects, the target tissue is the liver, heart, kidney and / or spleen.

[0176] In some embodiments, the present technology provides a method of treating Fabry disease or alleviating one or more symptoms of Fabry disease in a subject, comprising administering an engineered peptide comprising α-GAL A, a viral vector expressing α-GAL A, or a pharmaceutical composition comprising an engineered peptide comprising α-GAL A or a viral vector expressing α-GAL in a subject in need thereof.

[0177] In some embodiments, the present technology provides a method of increasing the expression of α-GAL A in a subject, comprising administering to a subject in need thereof an engineered peptide comprising α-GAL A, a viral vector expressing α-GAL A, or a pharmaceutical composition comprising an engineered peptide comprising α-GAL A or a viral vector expressing α-GAL A.

[0178] In some embodiments, the present technology provides a method for reducing lyso-Gb3 in a target tissue and / or plasma of a subject. In some aspects, the present technology provides a method for increasing the glycosylation of α-GAL A in a target tissue and / or plasma of a subject. In some aspects, the present technology provides a method for increasing mature α-GAL A in a target tissue and / or plasma of a subject.

[0179] In some aspects, the present technology provides a method for regulating sphingolipid storage in a target tissue and / or plasma in a subject. In some aspects, the regulation of sphingolipid storage is to reduce or increase sphingolipids in the target tissue and / or plasma of the subject. In some embodiments, the present technology provides a method for reducing sphingolipid storage in one or more targeted tissues of a subject, comprising administering an engineered peptide comprising α-GAL A, a viral vector expressing α-GAL, or a pharmaceutical composition comprising an engineered peptide comprising α-GAL A or a viral vector expressing α-GAL A in a desired subject.

[0180] dose

[0181] The appropriate dose can be selected according to the indication, severity and route of administration, such as high doses with less frequent administration for acute symptoms, and low doses for chronic symptoms requiring frequent and long-term treatment. High doses of engineered peptides, viral vectors and / or pharmaceutical compositions can be used in tissues with high lyso-Gb3 levels or low α-GAL A expression. The dose can be determined by the degree of reduction in α-GAL A expression and the effective amount of the engineered peptide, viral vector and / or pharmaceutical composition that can improve symptoms or molecular phenomena associated with Fabry disease.

[0182] The dosage of the engineered peptide, viral vector and / or pharmaceutical composition expressing α-GAL A can be determined by the effective dosage that can increase the expression and / or activity of α-GAL A, reduce lyso-GB3 or reduce the symptoms associated with Fabry disease. The engineered peptide, viral vector and / or pharmaceutical composition can be administered to a subject in need in a single dose or multiple doses.

[0183] In some embodiments, the engineered peptide, viral vector, and / or pharmaceutical composition is administered once to the subject.

[0184] In some aspects, the engineered peptide, viral vector, and / or pharmaceutical composition is administered with a second Fabry disease treatment.

[0185] It should be understood that for a subject, a specific dosage regimen should be adjusted over time based on the severity of the disease or the disease-related symptoms of the subject as required, for example, when a lower dose does not provide sufficient therapeutic activity, the dose of the engineered peptide, viral vector and / or pharmaceutical composition can be increased.

[0186] In some embodiments, the dosage is determined by the effective amount of the engineered peptide, viral vector and / or pharmaceutical composition that can reduce one or more symptoms associated with Fabry disease. In some embodiments, the dosage is determined by the effective amount of the engineered peptide, viral vector and / or pharmaceutical composition that can increase the expression and / or activity of α-GAL A. In some embodiments, the dosage is determined by the effective amount of the engineered peptide, viral vector and / or pharmaceutical composition that can reduce plasma and / or tissue lyso-Gb3 levels.

[0187] The dosage of the viral vector and / or pharmaceutical composition comprising the viral vector can be adjusted according to the specific load of the viral genome desired to be delivered to the subject in need thereof.

[0188] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dose of at least about 0.5E+10 vg / kg to 14E+14 vg / kg.

[0189] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dose of at least about 0.5E+10 vg / kg to 7E+10 vg / kg. In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dose of at least about 0.5E+10 vg / kg, at least about 1E+10 vg / kg, at least about 1.5E+10 vg / kg, at least about 2E+10 vg / kg, at least about 2.5E+10 vg / kg, at least about 3E+10 vg / kg, at least about 3.5E+10 vg / kg, at least about 4E+10 vg / kg, at least about 4.5E+10 vg / kg, at least about 5E+10 vg / kg, at least about 5.5E+10 vg / kg, at least about 6E+10 vg / kg, at least about 6.5E+10 vg / kg, or at least about 7E+10 vg / kg.

[0190] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of at least about 0.5E+10vg / kg to 7E+10vg / kg. In some aspects, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of at least 0.5E+10vg / kg, at least 1E+10vg / kg, at least 1.5E+10vg / kg, at least 2E+10vg / kg, at least 2.5E+10vg / kg, at least 3E+10vg / kg, at least 3.5E+10vg / kg, at least 4E+10vg / kg, at least 4.5E+10vg / kg, at least 5E+10vg / kg, at least 5.5E+10vg / kg, at least 6E+10vg / kg, at least 6.5E+10vg / kg, or at least 7E+10vg / kg.

[0191] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of about 0.5E+10vg / kg to 7E+10vg / kg. In some aspects, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of about 0.5E+10vg / kg, about 1E+10vg / kg, about 1.5E+10vg / kg, about 2E+10vg / kg, about 2.5E+10vg / kg, about 3E+10vg / kg, about 3.5E+10vg / kg, about 4E+10vg / kg, about 4.5E+10vg / kg, about 5E+10vg / kg, about 5.5E+10vg / kg, about 6E+10vg / kg, about 6.5E+10vg / kg, or about 7E+10vg / kg.

[0192] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dose of at least about 0.5E+11vg / kg to 7E+11vg / kg. In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dose of at least about 0.5E+11vg / kg, at least about 1E+11vg / kg, at least about 1.5E+11vg, at least about 2E+11vg / kg, at least about 2.5E+11vg / kg, at least about 3E+11vg / kg, at least about 3.5E+11vg / kg, at least about 4E+11vg / kg, at least about 4.5E+11vg / kg, at least about 5E+11vg / kg, at least about 5.5E+11vg / kg, at least about 6E+11vg / kg, at least about 6.5E+11vg / kg, or at least about 7E+11vg / kg.

[0193] In some embodiments, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of at least 0.5E+11vg / kg to 7E+11vg / kg. In some aspects, the engineered peptide, viral vector and / or pharmaceutical composition is administered at a dosage of at least 0.5E+11vg / kg, at least 1E+11vg / kg, at least 1.5E+11vg / kg, at least 2E+11vg / kg, at least 2.5E+11vg / kg, at least 3E+11vg / kg, at least 3.5E+11vg / kg, at least 4E+11vg / kg, at least 4.5E+11vg / kg, at least 5E+11vg / kg, at least 5.5E+11vg / kg, at least 6E+11vg / kg, at least 6.5E+11vg / kg, or at least 7E+11vg / kg.

[0194] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+11vg / kg to 7E+11vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+11vg / kg, about 1E+11vg / kg, about 1.5E+11vg, about 2E+11vg / kg, about 2.5E+11vg / kg, about 3E+11vg / kg, about 3.5E+11vg / kg, about 4E+11vg / kg, about 4.5E+11vg / kg, about 5E+11vg / kg, about 5.5E+11vg / kg, about 6E+11vg / kg, about 6.5E+11vg / kg, or about 7E+11vg / kg.

[0195] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+12vg / kg to 7E+12vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+12vg / kg, at least about 1E+12vg / kg, at least about 1.5E+12vg / kg, at least about 2E+12vg / kg, at least about 2.5E+12vg / kg, at least about 3E+12vg / kg, at least about 3.5E+12vg / kg, at least about 4E+12vg / kg, at least about 4.5E+12vg / kg, at least about 5E+12vg / kg, at least about 5.5E+12vg / kg, at least about 6E+12vg / kg, at least about 6.5E+12vg / kg, or at least about 7E+12vg / kg.

[0196] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+12vg / kg to 7E+12vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+12vg / kg, at least 1E+12vg / kg, at least 1.5E+12vg / kg, at least 2E+12vg / kg, at least 2.5E+12vg / kg, at least 3E+12v / kg, at least 3.5E+12vg / kg, at least 4E+12vg / kg, at least 4.5E+12vg / kg, at least 5E+12vg / kg, at least 5.5E+12vg / kg, at least 6E+12vg / kg, at least 6.5E+12vg / kg, or at least 7E+12vg / kg.

[0197] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+12vg / kg to 7E+12vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+12vg / kg, about 1E+12vg / kg, about 1.5E+12vg / kg, about 2E+12vg / kg, about 2.5E+12vg / kg, about 3E+12v / kg, about 3.5E+12vg / kg, about 4E+12vg / kg, about 4.5E+12vg / kg, about 5E+12vg / kg, about 5.5E+12vg / kg, about 6E+12vg / kg, about 6.5E+12vg / kg, or about 7E+12vg / kg.

[0198] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+13vg / kg to 7E+13vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+13vg / kg, at least about 1E+13vg / kg, at least about 1.5E+13vg, at least about 2E+13vg / kg, at least about 2.5E+13vg / kg, at least about 3E+13vg / kg, at least about 3.5E+13vg / kg, at least about 4E+13vg / kg, at least about 4.5E+13vg / kg, at least about 5E+13vg / kg, at least about 5.5E+13vg / kg, at least about 6E+13vg / kg, at least about 6.5E+13vg / kg, or at least about 7E+13vg / kg.

[0199] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+13vg / kg to 7E+13vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+13vg / kg, at least 1E+13vg / kg, at least 1.5E+13vg, at least 2E+13vg / kg, at least 2.5E+13vg / kg, at least 3E+13vg / kg, at least 3.5E+13vg / kg, at least 4E+13vg / kg, at least 4.5E+13vg / kg, at least 5E+13vg / kg, at least 5.5E+13vg / kg, at least 6E+13vg / kg, at least 6.5E+13vg / kg, or at least 7E+13vg / kg.

[0200] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+13vg / kg to 7E+13vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+13vg / kg, about 1E+13vg / kg, about 1.5E+13vg / kg, about 2E+13vg / kg, about 2.5E+13vg / kg, about 3E+13vg / kg, about 3.5E+13vg / kg, about 4E+13vg / kg, about 4.5E+13vg / kg, about 5E+13vg / kg, about 5.5E+13vg / kg, about 6E+13vg / kg, about 6.5E+13vg / kg, about 7E+13vg / kg.

[0201] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+14vg / kg to 7E+14vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least about 0.5E+14vg / kg, at least about 1E+14vg / kg, at least about 1.5E+14vg / kg, at least about 2E+14vg / kg, at least about 2.5E+14vg / kg, at least about 3E+14vg / kg, at least about 3.5E+14vg / kg, at least about 4E+14vg / kg, at least about 4.5E+14vg / kg, at least about 5E+14vg / kg, at least about 5.5E+14vg / kg, at least about 6E+14vg / kg, at least about 6.5E+14vg / kg, or at least about 7E+14vg / kg.

[0202] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+14vg / kg to 7E+14vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of at least 0.5E+14vg / kg, at least 1E+14vg / kg, at least 1.5E+14vg / kg, at least 2E+14vg / kg, at least 2.5E+14vg / kg, at least 3E+14vg / kg, at least 3.5E+14vg / kg, at least 4E+14vg / kg, at least 4.5E+14vg / kg, at least 5E+14vg / kg, at least 5.5E+14vg / kg, at least 6E+14vg / kg, at least 6.5E+14vg / kg, or at least 7E+14vg / kg.

[0203] In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+14vg / kg to 7E+14vg / kg. In some embodiments, the engineered peptide, viral vector and / or composition is administered at a dose of about 0.5E+14vg / kg, about 1E+14vg / kg, about 1.5E+14vg / kg, about 2E+14vg / kg, about 2.5E+14vg / kg, about 3E+14vg / kg, about 3.5E+14vg / kg, about 4E+14vg / kg, about 4.5E+14vg / kg, about 5E+14vg / kg, about 5.5E+14vg / kg, about 6E+14vg, about 6.5E+14vg / kg, or about 7E+14vg / kg.

[0204] Various equivalent substitutions, changes and modifications may be made to the dosage without departing from the scope of the present technology, and such equivalent embodiments are also included herein.

[0205] The following examples are intended to illustrate various embodiments of the present technology. Therefore, the specific embodiments discussed should not limit the scope of application of the present technology.

[0206] Example

[0207] Fabry disease results from decreased activity or expression of α-galactosidase A (α-GAL A).

[0208] α-GAL A function can be restored using gene therapy methods, such as exogenous expression of α-GALA via viral vectors. A series of viral vectors expressing α-GAL were constructed to verify that α-GAL A delivery can be achieved through vector-mediated delivery ( Figure 1A and 1B Each vector comprises an expression cassette, which comprises a wt hGLA nucleotide sequence (SEQ ID NO: 25) or a functional variant thereof such as hGLA cov1 (SEQ ID NO: 26), and an endogenous wt signal peptide (wt sp) nucleotide sequence of hGLA or a heterologous sp nucleotide sequence such as sp1-sp22 shown in Table 2.

[0209] Vector generation: mRNA was extracted from HEK293 cells and reverse transcribed into cDNA. The wt signal peptide at the N-terminus of hGLA was replaced with a heterologous sp sequence by PCR, and the fragment was cloned into a plasmid after restriction enzyme digestion. The nucleotide sequence encoding the fusion of α-GAL A with wt sp or any one of sp1 to sp22 was cloned into an expression vector containing the liver-specific TTR promoter, polyadenylation sequence, and AAV2 inverted terminal repeats (ITRs). The expression vector was verified by restriction digestion and Sanger sequencing and packaged into a single-stranded rAAV8 vector (ss-rAAV; Figure 1A ) or self-complementary rAAV8 vector (sc-rAAV, Figure 1B ).

[0210] Unless otherwise stated, in the Examples section, low dose refers to 2E+12 vg / kg, medium dose refers to 5E+12 vg / kg, high dose refers to 5E+13 vg / kg, wild-type mice refer to healthy mice without Fabry disease and treated with PBS, untreated mice refer to Fabry mice treated with PBS, PBS was used as the solvent for viral vector injection, and Rec.hAGA refers to recombinant human α-GAL A, which was used as a positive control for in vitro glycosylation assays.

[0211] Example 1: rAAV expressing α-GAL A fused to several heterologous sp increased the expression and activity of α-GAL in HepG2 cells and Fabry mice.

[0212] Plasmids expressing α-GAL A fused with sp1, sp2, ... or sp22 were transfected into HepG2 cells to test whether fusion with heterologous sp could increase the expression of α-GAL. Western blotting (WB) was used to detect the expression level of α-GAL A in the cell culture medium. Compared with α-GAL A fused with wt sp, fusions with sp1, sp3, sp4, sp18 and sp20-22 increased the extracellular secretion of α-GAL ( Figure 2A ) and increased α-GAL activity ( Figure 2B This indicates that replacing wt sp with heterologous sp can improve the expression and secretion of α-GAL A.

[0213] rAAV genomic DNA (gDNA) and hGLA RNA were measured in the liver of Fabry mice 12 weeks after injection with low, medium, or high doses of ss-wtspGLA or ss-sp21GLA to assess the genomic expression and distribution of injected ss-sp21GLA. Quantitative levels of rAAV8 genomes in the liver 12 weeks after injection showed a dose-dependent effect, with higher genome levels of both vectors detected after high-dose injection, indicating that high-dose injections resulted in higher transduction efficiency than low-dose injections ( Figure 3A At 12 weeks after injection, mRNA level detection had the same trend as genomic level quantification ( Figure 3B ). Viral genomes were detected in the liver samples of the two viral vector-treated groups, indicating that both viral vectors were transduced; transgenic mRNA was also detected in the liver samples, indicating that both viral vectors achieved transgenic transcription. Successful transduction and transcription of transgenes are prerequisites for effective treatment.

[0214] Fabry mice were injected with 2E+12vg / kg (low dose), 5E+12vg / kg (medium dose), or 5E+13vg / kg (high dose) of rAAV vector expressing α-GAL A fused to wt-sp (ss-wtspGLA) or rAAV vector expressing α-GALA fused to heterologous sp21 (ss-sp21GLA) to test whether α-GAL A fused to heterologous sp increased α-GAL A activity in Fabry mice. At 0, 2, 6, 8, and 12 weeks after injection, plasma was prepared from orbital blood of mice and α-GAL A activity in plasma was quantified. Both vectors produced higher levels of α-GAL A activity compared with control Fabry mice ( Figure 4 In the three dose groups, higher levels of plasma α-GAL A activity were detected in mice injected with ss-sp21GLA compared with mice injected with ss-wtspGLA ( Figure 4 ), and the highest plasma α-GAL A activity level was detected when ss-sp21GLA was injected at a high dose. At 12 weeks after injection, liver, heart, kidney, and spleen tissues of mice treated under the above conditions were collected. The results showed that in mice injected with ss-sp21GLA, the total α-GAL A activity level in different organs had a dose-dependent effect, while the total α-GALA activity level in different organs in mice treated with ss-wtspGLA showed less dose effect ( Figure 5A -D, corresponding to liver, heart, kidney and spleen tissues respectively).

[0215] Example 2: rAAV expressing α-GAL A fused to sp21 increases the expression of α-GAL in the liver, heart and kidney of Fabry mice.

[0216] Liver samples from Fabry mice were examined 12 weeks after injection with low, medium, or high doses of ss-sp21GLA or ss-wtspGLA to assess whether ss-sp21GLA administration could increase hepatic expression of α-GAL A and produce an active form with post-translational modifications. Fig. 6A and Figure 7 As shown, mice treated with three doses of ss-sp21GLA showed higher levels of α-GAL A in the liver, heart, and kidney compared with mice treated with ss-wtspGLA. In addition, glycosylation analysis of liver proteins 12 weeks after injection showed that α-GAL A produced by both vectors was glycosylated and processed to the mature form ( Figure 6B). The above results indicate that compared with ss-wtspGLA, ss-sp21GLA administration increased the level of α-GAL A in the liver of Fabry mice, and both vectors can produce glycosylated mature α-GAL A. Recombinant α-GAL A was used as a positive control for in vitro glycosylation assay (Rec.hAGA).

[0217] Example 3: rAAV expressing α-GAL A fused to sp21 reduces lyso-Gb3 levels and can slow weight gain without disturbing tissue structure.

[0218] α-GAL A deficiency may lead to the progressive and systemic accumulation of sphingolipids such as globotriaosylceramide (Gb3) and its deacylated derivative globotriaosylsphingosine (lyso-Gb3), and restoration of α-GAL A may reduce Gb3 and lyso-Gb3 levels. Fabry mice were treated with low, medium, or high doses of ss-sp21GLA or ss-wtspGLA to test whether ss-sp21GLA can effectively reduce lyso-Gb3 levels. At 12 weeks after injection ( Fig. 8A ) and 26 weeks ( Figure 8B ), a higher level of lyso-Gb3 decrease was detected in the ss-sp21GLA-injected group at all injection doses compared with the ss-wtspGLA-injected mice. This suggests that ss-sp21GLA showed superior efficacy in reducing lyso-Gb3 compared with ss-wtspGLA administration.

[0219] Fabry mice were treated with low, medium or high doses of ss-sp21GLA or ss-wtspGLA to test whether ss-sp21GLA administration affects mouse growth, that is, whether the treatment is safe. Body weight was recorded at 0, 2, 4, 6 and 9 weeks after injection. The results showed that the rate of weight gain was generally similar during growth, but the body weight of mice injected with medium or high doses of ss-sp21GLA and medium doses of ss-wtspGLA decreased slightly 4 weeks after injection ( Fig. 9 ). This suggests that ss-sp21GLA administration may result in slower weight gain at some doses.

[0220] Liver tissues from WT mice, untreated Fabry mice, and Fabry mice treated with high-dose ss-wtspGLA or ss-sp21GLA were collected and stained with hematoxylin-eosin (HE) to evaluate whether ss-sp21GLA administration had a negative impact on the liver in terms of expression of α-GAL A. No obvious pathological changes were observed in the livers of treated Fabry mice. This suggests that high-dose ss-sp21GLA administration did not cause harm to the liver.

[0221] Example 4: Functional variants of the hGLA nucleotide sequence encoding α-GAL A increased the expression of α-GAL in HepG2 cells and mouse tissues.

[0222] Plasmids containing a functional variant of wt SP (wt SPc.o.) and a functional variant of wt hGLA, hGLA cov1 (also referred to as "cohGLA"), were transfected into HepG2 cells, and the expression of α-GAL A in the protein lysate was detected to test whether modification of the wthGLA nucleotide sequence could increase the expression of α-GAL A. Fig.11 As shown, transfection of the hGLA cov1 nucleotide sequence was associated with increased expression of α-GAL A, indicating that optimizing the wt hGLA nucleotide sequence to hGLA cov1 can increase the expression of α-GAL in cells.

[0223] Fabry mice were injected with low or medium doses of ss-sp21GLA, FD802-1, FD802-2, FD802-3, or FD802-4 to evaluate whether sc-rAAV vectors containing hGLA cov1 nucleotide sequences can modulate the expression and activity of α-GAL A in mice. Plasma α-GAL A activity was quantified at 0, 2, 4, 6, and 8 weeks after injection. Fig.12 As shown, higher α-GAL A activity was detected after administration of FD802-1, 2, 3 and 4 vectors containing the hGLA cov1 nucleotide sequence compared to injection of ss-sp21GLA. Fig.13 and 14 As shown, compared with the ss-sp21GLA administration group at the same dose, the administration of FD802-1, 2, 3 and 4 containing the hGLAc.o.v1 nucleotide sequence increased the activity of α-GAL A in the liver, heart, kidney and spleen. The above results indicate that the hGLA cov1 nucleotide sequence increased the expression and activity of α-GAL A compared with the wt hGLA nucleotide sequence.

[0224] Example 5: The functional variant of the hGLA nucleotide sequence encoding α-GAL A increased the expression of α-GAL in the liver of mice, reduced the level of lyso-Gb3, and did not cause pathological changes in the liver.

[0225] At 14 weeks after injection of the medium dose of FD802-1, FD802-2, FD802-3, FD802-4, and ss-sp21GLA, liver samples from Fabry mice were collected and assayed for α-GAL A expression to assess whether the hGLA cov1 nucleotide sequence produced higher hepatic α-GAL A expression than the wthGLA nucleotide sequence ( Fig.15). The expression level of α-GAL A in the liver of mice in the FD802-1, FD802-2, FD802-3 or FD802-4 administration groups was higher than that in the ss-sp21GLA administration group, and the highest α-GAL A expression level was detected in the FD802-4 administration group ( Fig.15 ).

[0226] Furthermore, glycosylation analysis of liver proteins 14 weeks after injection of FD802-1, 2, 3, and 4 vectors containing hGLA cov1 showed that α-GAL A produced by the vectors was glycosylated and processed into the mature form ( Fig.16 ). Recombinant α-GAL A was used as a positive control for in vitro glycosylation assay (Rec.hAGA).

[0227] As mentioned above, α-GAL A deficiency may lead to progressive and systemic accumulation of sphingolipids such as Gb3 and its deacylated derivative lyso-Gb3, and restoration of α-GAL A may reduce Gb3 and lyso-Gb3 levels. Fabry mice were injected with low or medium doses of FD802-2, FD802-3, FD802-4, and ss-sp21GLA vectors to determine whether FD802-1, 2, 3, and 4 vectors containing the hGLA cov1 nucleotide sequence can effectively reduce lyso-Gb3. LC-MS / MS was used to analyze the Fabry mice 6 weeks after injection ( Fig.17A ) and 14 weeks ( Fig. 17B ) Quantitative detection of lyso-Gb3 in plasma confirmed that α-GALA in the treated mice could effectively reduce substrate levels compared with the untreated mice, and the effect was dose-dependent. Compared with ss-sp21GLA, FD802-1, FD802-2, FD802-3 and FD802-4 produced better Lyso-Gb3 clearance. In the mice treated with low or medium doses, the residual substrate level was less than 5% of the untreated control at 6 weeks after injection ( Fig.17A ), and FD802-4 administration achieved the best clearance in mice. Administration of four sc-AAV8 vectors (FD802-1, FD802-2, FD802-3, and FD802-4) produced higher α-GAL A activity levels in mice.

[0228] Liver tissues of untreated Fabry mice and Fabry mice in the medium-dose FD802-1, FD802-2, FD802-3, FD802-4, or ss-sp21GLA-administered groups were collected to evaluate whether administration of FD802-1, FD802-2, FD802-3, and FD802-4 vectors containing the hGLA cov1 nucleotide sequence altered tissue structure. H&E staining analysis showed that no pathological changes were observed in the livers of Fabry mice in the medium-dose FD802-1, 2, 3, and 4 administration groups, as Fig.18 The above results can prove the safety of treating Fabry mice with medium doses of FD802-1, FD802-2, FD802-3, and FD802-4 vectors containing hGLA cov1 nucleotide sequences.

[0229] Example 6: Successful expression of α-GAL A using other vector serotypes.

[0230] HepG2 cells were transduced with FD802-4 of rAAV1, rAAV2, ... or rAAV10 and the α-GAL A activity was detected to verify whether rAAV of different serotypes could produce the expression of α-GAL A. WB results confirmed that α-GAL A delivered by rAAV of various serotypes was expressed (lysate) and secreted (culture medium) in HepG2 cells ( Fig.19A ). The activity analysis of α-GAL A showed that the α-GAL A produced by the above-mentioned vector was processed into an active form ( Fig.19B ), serotype rAAV6 corresponds to the highest α-GAL A activity. The differences in expression and activity levels between the above vectors may be due to different viral packaging efficiencies. The above results indicate that various serotypes of AAV can transduce and express α-GAL A in human cells for therapeutic use.

[0231] Example 7: Fusion of α-GAL A to TAT p47-57 does not alter the secreted α-GAL A activity.

[0232] HepG2 cells were transfected with plasmids containing the cell-penetrating peptide TAT nucleotide sequence (TAT, which is the wild-type nucleotide sequence expressing TAT p47-57), wtSP co and hGLA cov1, and plasmids containing hGLA cov1 and wtSP co, respectively, and the activity of secreted α-GAL A was detected to test whether fusion expression of tat increases the activity of α-GAL A. The results of quantifying the activity of α-GAL A by taking equal amounts of culture medium showed that compared with hGLA (GLAco) without fusion of TAT p47-57, the plasmid fused with TATp47-57 (Ctat-GLAco) produced a lower level of α-GAL A activity ( Fig. 20A ). Equal amounts of α-GAL A protein were taken to quantify the activity level, and no difference was shown between the two plasmids ( Fig. 20B The above results indicate that the fusion of TAT p47-57 reduces the expression or secretion of hGLA transgene, but does not affect the activity of α-GAL A.

[0233] Example 8: Fusion of α-GAL A with TAT p47-57 increases the tissue permeability of α-GAL A, has no effect on the expression or glycosylation of α-GAL, and does not change the clearance efficiency of lyso-Gb3.

[0234] Fabry mice were injected with low or medium doses of FD802-3 or FD802-5 ( Figure 1B As shown), wherein FD802-5 contains the TAT nucleotide sequence, to test whether α-GAL A fused with TAT p47-57 can increase α-GAL A activity relative to when TAT is not fused. Fig.21A As shown, compared with the untreated mice, the mice in the FD802-3 or FD802-5 administration group showed higher levels of α-GAL A activity, and the FD802-5 vector administration group showed a dose-dependent effect. 14 weeks after injection of low or medium doses of FD802-3 or FD802-5, the α-GAL A activity levels in the liver, heart, kidney and spleen of Fabry mice were detected. The α-GAL A activity in the liver of the vector-administered group expressing TAT p47-57 (FD802-5) was slightly reduced, but the α-GAL A activity levels in the heart and kidney were slightly increased ( Fig. 21B ). Immunohistochemistry data of tissue samples taken 14 weeks after injection confirmed the expression of α-GAL A in the liver of mice given the medium dose. Higher α-GAL A protein levels were detected in the hearts of Fabry mice injected with FD802-5 compared with Fabry mice injected with FD802-3 ( Fig. 22 ). The above results indicate that administration of a vector expressing α-GAL A fused to TAT p47-57 can improve the tissue permeability of α-GAL in some tissue types.

[0235] The expression and glycosylation of α-GAL A in liver samples of Fabry mice were examined 14 weeks after injection of medium-dose FD802-3 or FD802-5 to assess whether the fusion of TAT p47-57 with α-GAL A affects the hepatic expression or glycosylation of α-GAL. Fig.23AAs shown, compared with the untreated mice, the mice in the FD802-3 and FD802-5 groups had higher α-GAL A expression levels, but there was no significant difference in α-GAL A expression between the FD802-3 and FD802-5 groups. Glycosylation analysis of liver proteins at 14 weeks after injection showed that α-GAL A produced by the two vectors was glycosylated and processed into active forms ( Fig. 23B The above results indicate that the fusion of TAT p47-57 and α-GAL A has no negative effect on the expression or glycosylation of α-GAL.

[0236] Fabry mice were treated with low or medium doses of FD802-3 and FD802-5 and lyso-Gb3 levels were measured to test whether the fusion of TAT p47-57 and α-GAL A could effectively reduce lyso-Gb3. Fig.24A ) and 14 weeks ( Fig. 24B ), plasma lyso-Gb3 levels were detected to decrease in both FD802-3 and FD802-5 administration groups, and FD802-5 showed a dose-dependent effect. Medium-dose FD802-3 and FD802-5 administration produced similar lyso-Gb3 clearance effects. The residual substrate levels in mice in the low-dose or medium-dose vehicle administration groups were less than 5% of the untreated control at 6 weeks after injection ( Fig.24A ).

[0237] H&E staining was used to evaluate liver tissues of Fabry mice treated with medium doses of FD802-3 or FD802-5. Fig.25 As shown, no observable negative effects on the liver were detected after administration. Administration of α-GAL A fused to TAT p47-57 did not alter tissue integrity, indicating the safety of the treatment.

Claims

1. An engineered peptide, which consists of human α-galactosidase a (α-GAL A) and a heterologous signal peptide, wherein the α-GAL A has a peptide sequence as shown in SEQ ID NO: 27; the heterologous signal peptide is selected from sp21, and the sp21 has a peptide sequence as shown in SEQ ID NO: 49; wherein the sp21 is fused to the N-terminus of α-GAL A.

2. The engineered peptide according to claim 1, further comprising a cell-penetrating peptide; the cell-penetrating peptide has a peptide sequence as shown in SEQ ID NO: 55-63; wherein the cell-penetrating peptide is fused to the C-terminus of the α-GAL A.

3. A viral vector comprising a nucleotide sequence encoding the engineered peptide according to claim 1 or 2. The viral vector according to claim 3 , further comprising a promoter.

5. A viral vector comprising an expression cassette and a promoter, wherein the expression cassette comprises a nucleotide sequence encoding the engineered peptide according to claim 1 or 2.

6. The viral vector of claim 3, wherein the nucleotide sequence encoding α-GAL A such as SEQ ID NO: 25 or 26 has a nucleotide sequence of at least 80%, 85%, 90%, 95%, 99% or 100% identity.

7. The viral vector of claim 4, wherein the nucleotide sequence encoding α-GAL A such as SEQ ID NO: 25 or 26 has a nucleotide sequence of at least 80%, 85%, 90%, 95%, 99% or 100% identity.

8. The viral vector of claim 5, wherein the nucleotide sequence encoding α-GAL A such as SEQ ID NO: 25 or 26 has a nucleotide sequence of at least 80%, 85%, 90%, 95%, 99% or 100% identity.

9. The viral vector according to claim 3, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

10. The viral vector as claimed in claim 4, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

11. The viral vector of claim 5, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

12. The viral vector of claim 6, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

13. The viral vector as claimed in claim 7, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

14. The viral vector of claim 8, wherein the nucleotide sequence encoding sp21 is the nucleotide sequence shown in SEQ ID NO:

22.

15. The viral vector of claim 3, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

16. The viral vector of claim 4, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

17. The viral vector of claim 5, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

18. The viral vector of claim 6, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

19. The viral vector of claim 7, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

20. The viral vector of claim 8, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

21. The viral vector of claim 9, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

22. The viral vector of claim 10, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

23. The viral vector of claim 11, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence of at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

24. The viral vector of claim 12, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

25. The viral vector of claim 13, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

26. The viral vector of claim 14, wherein the nucleotide sequence encoding the cell-penetrating peptide has a nucleotide sequence with at least 80%, 85%, 90%, 95%, 99% or 100% identity to SEQ ID NO:

24.

27. The viral vector of claim 4, wherein the promoter is a tissue-specific promoter.

28. The viral vector of claim 5, wherein the promoter is a tissue-specific promoter.

29. The viral vector of claim 7, wherein the promoter is a tissue-specific promoter.

30. The viral vector of claim 8, wherein the promoter is a tissue-specific promoter.

31. The viral vector of claim 10, wherein the promoter is a tissue-specific promoter.

32. The viral vector of claim 11, wherein the promoter is a tissue-specific promoter.

33. The viral vector of claim 16, wherein the promoter is a tissue-specific promoter.

34. The viral vector of claim 27, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

35. The viral vector of claim 28, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

36. The viral vector of claim 29, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

37. The viral vector of claim 30, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

38. The viral vector of claim 31, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

39. The viral vector of claim 32, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

40. The viral vector of claim 33, wherein the tissue-specific promoter is a liver-specific promoter, a heart-specific promoter, or a kidney-specific promoter.

41. The viral vector of claim 34, wherein the liver-specific promoter is a TTR promoter.

42. The viral vector of claim 35, wherein the liver-specific promoter is a TTR promoter.

43. The viral vector of claim 36, wherein the liver-specific promoter is a TTR promoter.

44. The viral vector of claim 37, wherein the liver-specific promoter is a TTR promoter.

45. The viral vector of claim 38, wherein the liver-specific promoter is a TTR promoter.

46. ​​The viral vector of claim 39, wherein the liver-specific promoter is a TTR promoter.

47. The viral vector of claim 40, wherein the liver-specific promoter is a TTR promoter.

48. The viral vector of claim 3, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

49. The viral vector of claim 4, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

50. The viral vector of claim 5, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

51. The viral vector of claim 6, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

52. The viral vector of claim 7, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

53. The viral vector of claim 8, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

54. The viral vector of claim 9, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

55. The viral vector of claim 15, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

56. The viral vector of claim 27, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

57. The viral vector of claim 34, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

58. The viral vector of claim 41, further comprising at least one inverted terminal repeat (ITR) nucleotide sequence, an intron, and a polyadenylation (polyA) nucleotide sequence.

59. The viral vector of claim 3, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

60. The viral vector of claim 4, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

61. The viral vector of claim 5, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

62. The viral vector of claim 6, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

63. The viral vector of claim 7, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

64. The viral vector of claim 8, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

65. The viral vector of claim 9, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

66. The viral vector of claim 15, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

67. The viral vector of claim 27, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

68. The viral vector of claim 34, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

69. The viral vector of claim 41, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

70. The viral vector of claim 48, wherein the viral vector is a modified recombinant adeno-associated virus (rAAV) vector.

71. Use of an engineered peptide as described in any one of claims 1-2, a viral vector as described in any one of claims 3-70, or a composition comprising an engineered peptide as described in any one of claims 1-2 or a viral vector as described in any one of claims 3-70 in the preparation of a medicament for treating Fabry disease in a subject or alleviating one or more symptoms of Fabry disease in a subject.

72. Use of an engineered peptide as described in any one of claims 1-2, a viral vector as described in any one of claims 3-70, or a composition comprising an engineered peptide as described in any one of claims 1-2 or a viral vector as described in any one of claims 3-70 in the preparation of a medicament for reducing sphingolipid storage in one or more targeted tissues of a subject.

73. The use of claim 71, wherein the subject has Fabry disease or has symptoms of Fabry disease.

74. The use of claim 72, wherein the subject has Fabry disease or has symptoms of Fabry disease.

75. The use of claim 72, wherein the one or more target tissues are selected from the group consisting of liver tissue, heart tissue or kidney tissue.

76. The use of claim 74, wherein the one or more target tissues are selected from the group consisting of liver tissue, heart tissue or kidney tissue.

77. The use of any one of claims 71-76, wherein the engineered peptide of any one of claims 1-2, the viral vector of any one of claims 3-70, or a composition comprising the engineered peptide of any one of claims 1-2 or the viral vector of any one of claims 3-70 is administered to the subject.

78. The use of any one of claims 71-76, wherein the engineered peptide of any one of claims 1-2, the viral vector of any one of claims 3-70, or a composition comprising the engineered peptide of any one of claims 1-2 or the viral vector of any one of claims 3-70 is administered to the subject once every 12 months.

79. The use of any one of claims 71-76, wherein the engineered peptide of any one of claims 1-2, the viral vector of any one of claims 3-70, or a composition comprising the engineered peptide of any one of claims 1-2 or the viral vector of any one of claims 3-70 is administered to the subject by systemic administration.

80. The use of any one of claims 71-76, wherein the viral vector of any one of claims 3-70 or a composition comprising the viral vector of any one of claims 3-70 is administered to the subject at one or more doses of 0.5E+10 vg / kg to 7E+14 vg / kg.

Citation Information

Patent Citations

  • Overexpression of mammalian and viral proteins

    WO1996009378A1

  • Glycosylation of peptides via O-linked glycosylation sequences

    CN101516388A

  • Methods and compositions for the treatment of fabry disease

    CN113423419A

  • Compositions and methods for treating fabry disease

    WO2022155665A1